<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">67476</article-id><article-id pub-id-type="doi">10.7554/eLife.67476</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Short Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>6-Phosphogluconate dehydrogenase (6PGD), a key checkpoint in reprogramming of regulatory T cells metabolism and function</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-226370"><name><surname>Daneshmandi</surname><given-names>Saeed</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7817-3006</contrib-id><email>Daneshmandi2006@yahoo.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-116754"><name><surname>Cassel</surname><given-names>Teresa</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1700-932X</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-157214"><name><surname>Higashi</surname><given-names>Richard M</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-235181"><name><surname>Fan</surname><given-names>Teresa W-M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7292-8938</contrib-id><email>teresa.fan@uky.edu</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-227270"><name><surname>Seth</surname><given-names>Pankaj</given-names></name><email>sethpankaj829@gmail.com</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution>Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Division of Interdisciplinary Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Center for Environmental and Systems Biochemistry, University of Kentucky</institution><addr-line><named-content content-type="city">Lexington</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Sarin</surname><given-names>Apurva</given-names></name><role>Reviewing Editor</role><aff><institution>Institute for Stem Cell Science and Regenerative Medicine</institution><country>India</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Rath</surname><given-names>Satyajit</given-names></name><role>Senior Editor</role><aff><institution>Indian Institute of Science Education and Research (IISER)</institution><country>India</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>28</day><month>10</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e67476</elocation-id><history><date date-type="received" iso-8601-date="2021-02-12"><day>12</day><month>02</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-10-17"><day>17</day><month>10</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Daneshmandi et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Daneshmandi et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-67476-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-67476-figures-v1.pdf"/><abstract><p>Cellular metabolism has key roles in T cells differentiation and function. CD4<sup>+</sup> T helper-1 (Th1), Th2, and Th17 subsets are highly glycolytic while regulatory T cells (Tregs) use glucose during expansion but rely on fatty acid oxidation for function. Upon uptake, glucose can enter pentose phosphate pathway (PPP) or be used in glycolysis. Here, we showed that blocking 6-phosphogluconate dehydrogenase (6PGD) in the oxidative PPP resulted in substantial reduction of Tregs suppressive function and shifts toward Th1, Th2, and Th17 phenotypes which led to the development of fetal inflammatory disorder in mice model. These in turn improved anti-tumor responses and worsened the outcomes of colitis model. Metabolically, 6PGD blocked Tregs showed improved glycolysis and enhanced non-oxidative PPP to support nucleotide biosynthesis. These results uncover critical role of 6PGD in modulating Tregs plasticity and function, which qualifies it as a novel metabolic checkpoint for immunotherapy applications.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>regulatory T cell</kwd><kwd>metabolism</kwd><kwd>6PGD</kwd><kwd>immunoregulation</kwd><kwd>glucose</kwd><kwd>pentose phosphate pathway</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Bayer Fund</institution></institution-wrap></funding-source><award-id>2014-07-1112</award-id><principal-award-recipient><name><surname>Seth</surname><given-names>Pankaj</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000052</institution-id><institution>NIH Office of the Director</institution></institution-wrap></funding-source><award-id>1U24DK097215-01A1</award-id><principal-award-recipient><name><surname>Fan</surname><given-names>Teresa</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>P30CA177558</award-id><principal-award-recipient><name><surname>Fan</surname><given-names>Teresa</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>6-Phosphogluconate dehydrogenase controls regulatory T cells metabolism with shifts to Th1, Th2, and Th17 phenotypes.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Regulatory T cells (Tregs) are distinct subsets of CD4<sup>+</sup> T cells that limit inflammatory responses by suppressing self-reactive T cells to maintain balance between protective and excessive inflammation. Although lipid oxidation and the mevalonate pathway being considered key to their functions (<xref ref-type="bibr" rid="bib13">Michalek et al., 2011</xref>; <xref ref-type="bibr" rid="bib24">Timilshina et al., 2019</xref>), cellular metabolism in Tregs is an active area of investigation. Tregs depend on these pathways to maintain their suppressive functions, which are distinct from the high glycolytic signatures of conventional CD4<sup>+</sup> effector subsets, Th1, Th2, and Th17 (<xref ref-type="bibr" rid="bib13">Michalek et al., 2011</xref>). Although glycolysis is not major feature in Tregs, it is critical for Treg expansion (<xref ref-type="bibr" rid="bib16">Pacella et al., 2018</xref>). Glucose (Glc) enters the cell via glucose transporter 1 (Glut1) and is metabolized to glucose 6-phosphate (G6P), which has alternative fates via glycolysis and as the entry point into the pentose phosphate pathway (PPP) (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>).</p><p>The PPP, also known as the hexose monophosphate shunt or phosphogluconate pathway, comprises two interdependent branches: the oxidative branch and the non-oxidative branch. Oxidative PPP is composed of three essentially irreversible reactions in which the first is catalyzed by G6PD that converts G6P to 6-phosphogluconolactone (6PGL) while generating reduced nicotinamide adenine dinucleotide phosphate (NADPH). 6PGL then hydrolyzes to 6-phosphogluconate (6PG), which is oxidatively decarboxylated by 6-phosphogluconate dehydrogenase (6PGD), producing ribulose-5-phosphate and a second molecule of NADPH and (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). Ribulose-5-phosphate is the precursor for ribose-5-phophate (R5P) and thence nucleotides, and NADPH is required both for reductive anabolism and for antioxidative defense.</p><p>Tregs are known to have high rates of lipid oxidation (<xref ref-type="bibr" rid="bib13">Michalek et al., 2011</xref>), which would provoke antioxidant machinery which requires NADPH generated from PPP. We thus investigated the role of PPP in T CD4<sup>+</sup> subsets. Our preliminary studies using inhibitors of the PPP enzymes indicated that the third enzyme in the oxidative PPP, 6PGD, has critical roles in modulating T cell functions.</p><p>To assess the role of 6PGD in modulating Treg function, we generated mice with flox targeted <italic>Pgd</italic> allele (<italic>Pgd</italic><sup>fl/fl</sup>), which were crossed with <italic>Foxp3</italic><sup>YPF-Cre</sup> mice to generate <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>YPF-Cre</sup> (thereafter <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup>). Interestingly, <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice showed a distinct phenotype, namely spontaneous fatal autoimmunity and lower lifespan. Isolated <italic>Pgd</italic>-deficient Tregs had diminished suppressive functions both in vitro and in vivo. They also displayed shift in differentiation toward Th1, Th2, and Th17 CD4<sup>+</sup> T cell subtypes. Stable isotope tracing studies on sorted Tregs revealed reprogrammed metabolic pathways consistent with the generation of these subsets. Our results for Tregs directly isolated from pro-inflammatory mice model and derived from naïve CD4<sup>+</sup> T cells in vitro uncover a critical role of 6PGD in maintaining Tregs metabolism, phenotype, and function.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>PGD deficiency in Tregs induces spontaneous fatal autoimmunity</title><p>Our preliminary studies showed that pharmacological inhibitor of 6PGD (6-aminonicotinamide [6-AN]) but not G6PD inhibitor (dehydroepiandrosterone [DHEA]) enhances IFN-γ production by in vitro activated CD4<sup>+</sup> T cells (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>), while DHEA but not 6-AN at 10 µM instigated poor T cells viability (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). Based on these, we generated <italic>Pgd</italic><sup>fl/fl</sup> mice (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>) and crossed with <italic>Cd4</italic><sup>Cre</sup> mice (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F</xref>). An enhanced effector phenotype of T CD4<sup>+</sup> subsets was observed in <italic>Pgd</italic><sup>fl/fl</sup><italic>Cd4</italic><sup>Cre</sup> mice (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1I-J</xref>) suggesting altered regulation of T cell differentiation and/or activation.</p><p>To specifically delete 6PGD in Tregs, <italic>Pgd</italic><sup>fl/fl</sup> mice were crossed with <italic>Foxp3</italic><sup>Cre</sup> mice (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1G</xref>). In these mice, the Cre recombinase driven by the <italic>Foxp3</italic> promoter will delete <italic>Pgd</italic> only in Tregs upon <italic>Foxp3</italic> expression and YFP can be used as expression marker (<xref ref-type="bibr" rid="bib19">Rubtsov et al., 2008</xref>). <italic>Pgd</italic> deletion in YFP expressing cells was verified by western blot, real-time PCR (<xref ref-type="fig" rid="fig1">Figure 1A–B</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E</xref>), and stable isotope-resolved metabolomics (SIRM) analysis . Notably, disruption of 6PGD in Tregs led to a profound inflammatory disorder while <italic>Pgd</italic><sup>fl/fl</sup><italic>Cd4</italic><sup>Cre</sup> mice appeared normal (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1K-L</xref>). Compared with <italic>Foxp3</italic><sup>Cre</sup> (wild-type [WT]) controls at 20 days of age, <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice exhibited a reduced body size and crusting of ears and eyelids (<xref ref-type="fig" rid="fig1">Figure 1C</xref>), enlargement of peripheral lymphoid organs (<xref ref-type="fig" rid="fig1">Figure 1D</xref>), and lymphoproliferation (<xref ref-type="fig" rid="fig1">Figure 1E</xref>) that was accompanied by a significantly shorter lifespan (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Lymphoproliferation was attributed to a higher frequency of CD4<sup>+</sup> and CD8<sup>+</sup> T cells in spleen (<xref ref-type="fig" rid="fig1">Figure 1G</xref>) with increased frequencies of CD44<sup>high</sup>CD62L<sup>low</sup> effector/memory phenotype (<xref ref-type="fig" rid="fig1">Figure 1H</xref>), reduced frequencies of CD44<sup>low</sup>CD62L<sup>high</sup> naïve cells (<xref ref-type="fig" rid="fig1">Figure 1H</xref>), higher expressions of CD69 activation marker (<xref ref-type="fig" rid="fig1">Figure 1I</xref>), and enhanced production of IFN-γ (<xref ref-type="fig" rid="fig1">Figure 1J</xref>) in both CD4<sup>+</sup> and CD8<sup>+</sup> T cells. In these mice, CD8<sup>+</sup> T cells also produced more granzyme-B and higher cytotoxic marker CD107a expression (<xref ref-type="fig" rid="fig1">Figure 1K</xref>). The titers of serum antibodies were much higher in <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> than WT mice (<xref ref-type="fig" rid="fig1">Figure 1L</xref>). Moreover, <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice had a significant increase in serum levels of IFN-γ, IL-17A, IL-4, and IL-5 (<xref ref-type="fig" rid="fig1">Figure 1M</xref>). Along with splenomegaly and lymphadenopathy in <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice, there was an enhanced immune cell infiltration and tissue damage in main organs (<xref ref-type="fig" rid="fig1">Figure 1N</xref>). The development of observed fatal inflammatory disease in <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice suggests a crucial role of 6PGD in modulating the function of Tregs. Such phenotype has also been reported in association with central signaling elements of metabolic reprogramming such as mechanistic target of rapamycin (mTOR) (<xref ref-type="bibr" rid="bib32">Zeng et al., 2013</xref>) and liver kinase B1 (<xref ref-type="bibr" rid="bib30">Yang et al., 2017</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Deletion of 6-phosphogluconate dehydrogenase (6PGD) in regulatory T cells (Tregs) induces a fatal autoimmune phenotype.</title><p>(<bold>A–B</bold>) YFP<sup>+</sup> cells were sorted from <italic>Pgd</italic><sup>+/+</sup><italic>Foxp3</italic><sup>Cre</sup> (wild-type [WT]) and <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice and deletion of <italic>Pgd</italic> was confirmed by western blot (<bold>A</bold>) and real-time PCR (<bold>B</bold>). (<bold>C</bold>) Representative image of 21-day-old WT and <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice. (<bold>D</bold>) Representative image of lymphadenopathy in <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> compared to WT mice. (<bold>E</bold>) T cells absolute number per spleen and peripheral lymph nodes (pLNs) of WT and <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice are shown (N = 12 mice per group). (<bold>F</bold>) Survival curve of WT and <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice. Representation of 15 mice per group. (<bold>G</bold>) Splenocytes from 20-day-old WT and <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice were harvested and distribution of CD4<sup>+</sup> versus CD8<sup>+</sup> T cells were evaluated. (<bold>H</bold>) Deletion of 6PGD induces enhanced effector phenotype (CD44<sup>high</sup> CD62L<sup>low</sup>) both in CD4<sup>+</sup> T cells (top panel) and in CD8<sup>+</sup> T cells (bottom panel) in 20-day-old <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> compared to WT mice. (<bold>I</bold>) Both CD4<sup>+</sup> and CD8<sup>+</sup> T cells express higher levels of CD69 activation marker in <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> compared to WT mice. (<bold>J</bold>) Splenocytes from 20-day-old WT and <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice were stimulated with PMA (50 ng/ml)/ionomycin (1 μg/ml) plus GolgiPlug (1 μl/ml) for 4 hr and expression of IFN-γ was evaluated by flow cytometry. (<bold>K</bold>) Granzyme B (top panel) and CD107a degranulation activation marker (bottom panel) expression was assessed on splenocytes of 20-day-old WT and <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice by flow cytometry. (<bold>L–M</bold>) Serum was collected from 20-day-old WT and <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice and levels of serum antibodies (<bold>L</bold>) and IFN-γ, IL-17A, IL-4, and IL-5 (<bold>M</bold>) were detected as described in supplemental information. Results are representative of 12 mice per group. (<bold>N</bold>) Hematoxylin and eosin staining of lung: original magnification (<bold>X10</bold>), pancreas (<bold>X10</bold>), skin (<bold>X10</bold>), and intestine (<bold>X10</bold>) of WT and <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice. *p &lt; 0.05; **p &lt; 0.01; ***p &lt; 0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67476-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Effect of G6PD/6PGD inhibition and generation of <italic>Pgd</italic><sup>fl/fl</sup> <italic>Foxp3</italic><sup>cre</sup> mice.</title><p>(<bold>A</bold>) Schematic diagram interconnecting pentose phosphate pathway (PPP), glycolysis, gluconeogenesis, and the Krebs cycle. (<bold>B–C</bold>) IFN-γ production (<bold>B</bold>) and cell viability (<bold>C</bold>) by naïve CD4<sup>+</sup> T cells in the presence of 10 µM 6PGD inhibitor (6-aminonicotinamide [6-NA]), 10 µM G6PD inhibitor (dehydroepiandrosterone [DHEA]), or the vehicle DMSO. (<bold>D</bold>) Strategy for <italic>Pgd</italic> knockout by inserting the <italic>SA–ßgeo–pA</italic> (<italic>LacZ-Neo</italic>) cassette into the intron between exons 4 and 5 of <italic>6PGD</italic>, which disrupts gene function. The targeted <italic>Pgd</italic> exon 5 is flanked by <italic>loxP</italic> sites. (<italic>FRT</italic>, target site for FLP recombinase; <italic>loxP</italic>, target site for Cre-recombinase). Excision of the <italic>SA–ßgeo–pA</italic> cassette by FLP recombinase generated the heterozygous status of modified <italic>Pgd</italic> (<italic>Pgd</italic><sup>fl/+</sup>). Heterozygous mice were crossed to generate homozygous <italic>Pgd<sup>f</sup></italic><sup>l/fl</sup>. (<bold>E</bold>) PCR validation of the <italic>Pgd</italic><sup>fl/+</sup> and <italic>Pgd</italic><sup>fl/fl</sup> mice. (<bold>F–H</bold>) <italic>Pgd</italic><sup>fl/fl</sup> mice were crossed with <italic>Cd4</italic><sup>Cre</sup>, (<bold>F</bold>) <italic>Foxp3</italic><sup>YFP-Cre</sup>, (G) and <italic>Foxp3</italic><sup>EGFP-Cre-ERT2</sup> and (H) mice. (<bold>I–J</bold>) Enhanced effector cells phenotype in spleen of <italic>Pgd</italic><sup>fl/fl</sup><italic>Cd4</italic><sup>Cre</sup> mice. (<bold>K–L</bold>) <italic>Pgd</italic><sup>fl/fl</sup><italic>Cd4</italic><sup>Cre</sup> mice show normal body phenotype (<bold>K</bold>) and survival rate (<bold>L</bold>). HK: hexokinase; G6PD: glucose-6-phosphate dehydrogenase; L: lactonase; 6PGD: 6-phosphogluconate dehydrogenase; TK: transketolase; TA: transaldolase; PGI: phosphoglucose isomerase; LDH: lactate dehydrogenase; PEPCK: phosphoenolpyruvate carboxykinase.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67476-fig1-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Deletion of 6PGD in Tregs results in loss of their suppressive function</title><p>Based on the observed phenotype in <italic>Pgd</italic><sup>fl/fl</sup> <italic>Foxp3</italic><sup>Cre</sup> mice, we further evaluated specific phenotypic markers and suppressive functions of Tregs, which were either isolated from inflamed mice model or generated in vitro from naïve CD4<sup>+</sup> T cells. The CD4<sup>+</sup>Foxp3<sup>+</sup> cells in the spleen of 20-day-old <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice were lower than the WT counterparts, both in number (<xref ref-type="fig" rid="fig2">Figure 2A</xref>) and in frequency of total CD4<sup>+</sup> T cells (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). The expression of CD98 (a subunit of the neutral amino acid transporter), CD71 (the transferrin receptor), and CD40L in these 6PGD-deficient Tregs was enhanced (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). CD71 and CD98 are key nutrient receptors in Tregs that depend on mTORC1 (<xref ref-type="bibr" rid="bib10">Kelly et al., 2007</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>6-Phosphogluconate dehydrogenase (6PGD) blockade results in loss of suppressive function in regulatory T cells (Tregs).</title><p>(<bold>A–B</bold>) Frequency of CD4<sup>+</sup>Foxp3<sup>+</sup> cells in spleen of 20-day-old <italic>Pgd</italic><sup>+/+</sup><italic>Foxp3</italic><sup>Cre</sup> (wild type [WT]) was evaluated and demonstrated (<bold>A</bold>) in total cells or (<bold>B</bold>) in gated CD4<sup>+</sup> T cells. Bar graphs show respective statistical differences for percentage of Foxp3<sup>+</sup> cells and Foxp3 gMFI. (<bold>C</bold>) Expression of CD98, CD71, and CD40L on Tregs from WT and <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice. (<bold>D–E</bold>) YFP<sup>+</sup> cells were isolated from 20-day-old WT and <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice. (<bold>D</bold>) Purified YFP<sup>+</sup> cells are shown and (<bold>E</bold>) <italic>Foxp3</italic> mRNA levels were evaluated by real-time PCR. (<bold>F</bold>) Isolated Tregs (YFP<sup>+</sup>) were cultured in vitro in presence of IL-2 (700 IU/ml) and anti-CD3/anti-CD28 coaled beads (Treg:beads ratio 1:3) and cells number was assessed at 24 and 48 hr time points. Results are representative of three independent experiments with N = 4. (<bold>G</bold>) Cytokine release in media as cultured in above culture condition. (<bold>H–I</bold>) Isolated Tregs (YFP<sup>+</sup>) from <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice showed lower suppressive activity in suppression assay, as described in Materials and methods. Representative histogram of CFSE dilution pattern (Treg:Teff = 1:1 ratio) (<bold>H</bold>) and bar graph of T cell proliferation as a function of serial Treg:Teff ratios (<bold>I</bold>) are shown. Results are from three independent experiments with N = 4. (<bold>J</bold>) Tregs (YFP<sup>+</sup>) from WT and <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice and T effector (CD4<sup>+</sup>CD45RB<sup>high</sup>) cells were isolated, mixed, and transferred to <italic>Rag1</italic><sup>-/-</sup> mice as inflammatory bowel disease (IBD) model. Colons were evaluated 45 days after cells injection. (<bold>K</bold>) Weight change in IBD mouse model. (<bold>L</bold>) On day 45 post IBD induction <italic>Rag1</italic><sup>-/-</sup> mice colon were measured for length and thickness. (<bold>M</bold>) Representative hematoxylin and eosin staining of Rag1<sup>-/-</sup> mice colon on day 45 after IBD induction. Results are from two independent experiments with N = 8 per group. *p &lt; 0.05; **p &lt; 0.01; ***p &lt; 0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67476-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>6-Phosphogluconate dehydrogenase (6PGD) deficiency in regulatory T cells (Tregs) induces shift toward CD4<sup>+</sup> T helper subsets.</title><p>(<bold>A–B</bold>) Heat map and volcano plot representing gene expression in Tregs (YFP<sup>+</sup>) isolated from 20-day-old wild-type (WT) and <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice. (<bold>C</bold>) Real-time PCR assay was done on selected genes from Tregs isolated from WT and <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice. (<bold>D</bold>) Expression of CD25, ICOS, and CTLA-4 in Tregs (YFP<sup>+</sup>) from WT and <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice. (<bold>E–G</bold>) CD4<sup>+</sup> T cells in <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice spleen produced higher amount of IFN-γ, IL-13, and IL-17A. Results are representative of two independent experiments with N = 3 per group. **p &lt; 0.01; ***p &lt; 0.001; ****p &lt; 0.0001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67476-fig2-figsupp1-v1.tif"/></fig></fig-group><p>Next, YFP<sup>+</sup> (indicator of Foxp3 expression) cells (<xref ref-type="bibr" rid="bib19">Rubtsov et al., 2008</xref>) were sorted from 20-day-old WT (<italic>Foxp3</italic><sup>YFP-Cre</sup>) and <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice and evaluated for phenotypic and functional properties. YFP<sup>+</sup> sorted cells are demonstrated in <xref ref-type="fig" rid="fig2">Figure 2D</xref>. The level of Foxp3 transcript was lower in 6PGD-deficient cells evaluated by real-time PCR (<xref ref-type="fig" rid="fig2">Figure 2E</xref>), which is consistent with lower <italic>Foxp3</italic> gMFI in these cells (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). When culturing sorted YFP<sup>+</sup> Tregs in vitro in the presence of IL-2 (700 IU/ml) and anti-CD3/anti-CD28 coated beads (Treg:beads ratio 1:3), higher number of cells were detected for 6PGD-deficient cells at both 24 and 48 hr time points (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). This result showed that 6PGD deficiency was tolerable in Tregs and did not induce cell death in these cells. Evaluation of the culture media demonstrated significantly higher production of cytokines as markers for other CD4<sup>+</sup> T helper subsets such as IFN-γ (Th1), IL-13 and IL-5 (Th2), and IL-17A (Th17) due to 6PGD blockade (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). RNA sequencing (RNAseq) analysis of isolated Tregs from inflamed mice also demonstrated higher expression levels of Th1 (<italic>IFNg</italic>, <italic>Tbx21</italic>), Th2 (<italic>Il13</italic>, <italic>Il5</italic>, <italic>Il4</italic> and <italic>Gata3</italic>), and Th17 (<italic>Il17a</italic>) marker genes in 6PGD-deficient Tregs, shown as heat map in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref> and volcano plot in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>. RNAseq data were confirmed by real-time PCR for selected genes (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>) and flow cytometry (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>). It should be noted that although these shifts in gene expression are consequences of 6PGD blockade in Tregs, the resulting severe autoimmunity in mice with pro-inflammatory microenvironment should also be considered. Pro-inflammatory condition of mice could enhance or diminish some of these gene expression changes.</p><p>Although <italic>Foxp3</italic> expression is a key marker of the Treg formation, additional metabolic and transcriptional regulations can orchestrate Treg plasticity (<xref ref-type="bibr" rid="bib21">Shi and Chi, 2019</xref>). <italic>Pgd</italic>-deficient Tregs can be converted to Th1, Th2, and Th17 by modification of metabolic pathways. Notably, the Th2 markers <italic>IL13</italic> and <italic>IL5</italic> were among the most upregulated genes in <italic>Pgd</italic> deleted Tregs (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A-B</xref>), which points to Treg differentiation into Th2 type cells. These gene expression changes were consistent with significantly reduced suppressive capacity of <italic>Pgd</italic>-deficient versus WT Treg (<xref ref-type="fig" rid="fig2">Figure 2H–I</xref>), which was assayed by co-culturing the corresponding isolated YFP<sup>+</sup> cells with CD4<sup>+</sup>CD45RB<sup>high</sup> effector cells in vitro, as described in supplemental information. Altered Treg function was along with enhancement of CD4<sup>+</sup> T cells phenotype shift toward Th1, Th2, and Th17 cells subsets in <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E-G</xref>). Pro-inflammatory condition of mice could also contribute in the magnitude of these outcomes.</p><p>We also examined Tregs suppressive function in vivo using an inflammatory bowel disease (IBD) model (<xref ref-type="fig" rid="fig2">Figure 2J</xref>). YFP<sup>+</sup> cells from WT and <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice as well as WT CD4<sup>+</sup> T effector (CD4<sup>+</sup>CD45RB<sup>high</sup>) cells were isolated, mixed, and transferred to Rag1<sup>-/-</sup> mice (<xref ref-type="bibr" rid="bib15">Ostanin et al., 2009</xref>; <xref ref-type="bibr" rid="bib22">Steinbach et al., 2015</xref>). Higher rate of weight loss was observed in <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> group (<xref ref-type="fig" rid="fig2">Figure 2K</xref>) compared to WT. Colons were evaluated on day 45 post cells injection in the IBD model mice, 6PGD deficiency in Tregs led to shorter and thicker colons compared with no injection or injection with WT Treg (<xref ref-type="fig" rid="fig2">Figure 2L</xref>). Hematoxylin and eosin staining of colons demonstrated higher immune cell infiltration and destruction of colon structure (<xref ref-type="fig" rid="fig2">Figure 2M</xref>). Taken together these results confirm that 6PGD inhibition is associated with loss of Treg suppressive function, both in vitro and in vivo.</p></sec><sec id="s2-3"><title>6PGD deficiency attenuates Treg suppressive function and induces potent anti-tumor responses</title><p>To confirm key observations from YFP<sup>+</sup> sorted cells of <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice that displayed inflammatory condition, we characterized changes in the molecular properties of WT Tregs induced by the small molecule inhibitor of 6PGD, 6-AN (<xref ref-type="bibr" rid="bib3">Davis and Kauffman, 1987</xref>). We also examined the effect of 6PGD blockade in Tregs on tumor formation by tamoxifen treatment of <italic>Pgd</italic><sup>fl/fl</sup> <italic>Foxp3</italic><sup>EGFP-Cre-ERT2</sup> mice (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1H</xref> and <xref ref-type="fig" rid="fig3">Figure 3</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>6-Phosphogluconate dehydrogenase (6PGD) blockade in regulatory T cells (Tregs) prevents their suppressive function and induces potent anti-tumor responses.</title><p>(<bold>A–B</bold>) Wild-type (WT) <italic>Foxp3</italic><sup>Cre</sup> naïve CD4<sup>+</sup> T cells (CD62L<sup>high</sup> CD44<sup>low</sup>) were driven toward Tregs in vitro (as inducible Treg [iTreg]) along with treatment with 6-aminonicotinamide (6-AN) or vehicle DMSO and Treg drive efficacy was evaluated as CD25<sup>+</sup>YFP<sup>+</sup> cells. YFP<sup>+</sup> percentage in CD4<sup>+</sup> T cells (<bold>A</bold>) and YFP gMFI (<bold>B</bold>) are demonstrated. (<bold>C</bold>) Real-time PCR analysis on derived Tregs demonstrate lower expression of <italic>Foxp3</italic> transcription factor and higher expression of <italic>Gata3</italic> transcription factor and <italic>IL-5</italic> under treatment with 6-AN versus vehicle DMSO. (<bold>D–E</bold>) 6-AN treatment of driven Tregs demonstrate lower suppressive capacity evaluated in in vitro suppression assay. YFP<sup>+</sup> cells were sorted for the suppression assay. (<bold>F</bold>) Tamoxifen treatment schedule and tumor induction by implanting B16F10 cells in <italic>Pgd</italic><sup>fl/fl</sup> <italic>Foxp3</italic><sup>EGFP-Cre-ERT2</sup> and WT mice. (<bold>G</bold>) Flow cytometry analysis show the same frequency of Tregs (EGFP<sup>+</sup>) in CD4<sup>+</sup> cells in spleen of both mouse groups 10 days post tamoxifen treatment. (<bold>H</bold>) Suppression assay on sorted EGFP<sup>+</sup> Tregs as described in supplemental information. (<bold>I–J</bold>) 6PGD blockade in Tregs resulted in lower tumor volume (<bold>I</bold>) and tumor weight (<bold>J</bold>). (<bold>K–L</bold>) Tumor of the mouse models from (<bold>F</bold>) were evaluated for infiltration of both CD4<sup>+</sup> and CD8<sup>+</sup> T cells on day 16 post implantation, which were higher in 6PGD blocked mice, as shown by representative flowgram (<bold>K</bold>) and bar graphs (<bold>L</bold>). (<bold>M–O</bold>) Tumor infiltrating CD4<sup>+</sup> (<bold>M</bold>) and CD8<sup>+</sup> (<bold>N</bold>) T cells showed higher capacity of IFN-γ production on day 16. Results are from two independent experiments with N = 8 per group. *p &lt; 0.05; **p &lt; 0.01; ***p &lt; 0.001.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67476-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>6-Phosphogluconate dehydrogenase (6PGD) function in regulatory T cells (Tregs) is required for suppressing allergic (Th2) responses.</title><p>(<bold>A</bold>) Histochemical PAS (top) and Trichrome staining (bottom) of lungs from 20-day-old wild-type (WT) and <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice. In the lung of <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice, there was higher collagen deposit (top) and higher mucus accumulation (bottom) presented as blue colors. (<bold>B</bold>) Sorted YFP<sup>+</sup> Tregs from lungs expressed lower levels of Foxp3 and higher amount of Gata3 transcription factors in <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice determined by real-time PCR. (<bold>C</bold>) Lung of 20-day-old <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice demonstrated higher infiltration of T cells (both CD4<sup>+</sup> and CD8<sup>+</sup> cells). (<bold>D–I</bold>) Intracellular cytokine staining on lung and spleen for IL-13 (<bold>D–E</bold>), IL-5 (<bold>F–G</bold>), and IL-4 (<bold>H–I</bold>) in CD4<sup>+</sup> T cells. (<bold>J</bold>) Representative frequency of eosinophils (CD11c<sup>low</sup> Siglec-F<sup>+</sup>) in the mouse’s lung. (<bold>K</bold>) Flow cytometry analysis of splenic eosinophils (CD11b<sup>+</sup> Siglec-F<sup>+</sup>) and macrophages (CD11b<sup>+</sup> Siglec-F<sup>-</sup>). (<bold>L–M</bold>) Frequency of CD11b<sup>+</sup> Ly6G<sup>+</sup> cells in spleen and lung of 20-day-old <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> compared to WT mice. Results are representative of three independent experiments with N = 2–3 mice per group. **p &lt; 0.01.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67476-fig3-figsupp1-v1.tif"/></fig></fig-group><p>First, we used WT <italic>Foxp3</italic><sup>Cre</sup> naïve (CD62L<sup>high</sup> CD44<sup>low</sup>) CD4<sup>+</sup> T cells to generate Tregs in vitro (as inducible Tregs [iTregs]) in the polarization medium (IL-2+ TGF-β) plus 6-AN or vehicle DMSO. This medium effectively induced <italic>Foxp3</italic> expression indicated by the YFP marker in both 6-AN and DMSO treatments (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), with lower YFP gMFI in 6-AN treated cell (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Tregs generated under 6-AN treatment in vitro showed a lower level of <italic>Foxp3</italic> (<xref ref-type="fig" rid="fig3">Figure 3C</xref>)<italic>,</italic> but a higher level of <italic>Gata3</italic> and <italic>IL5</italic> (<xref ref-type="fig" rid="fig3">Figure 3C</xref>) expression. This difference in <italic>Foxp3/Gata3</italic> expression in generated Tregs in vitro indicates altered Treg properties in 6PGD blocked cells. Tregs generated in the presence of 6-AN also showed diminished suppressive function in vitro (<xref ref-type="fig" rid="fig3">Figure 3D–E</xref>).</p><p>To control the timing of <italic>Pgd</italic> deletion in Tregs and evaluate Tregs suppressive function under controlled inflammation, we generated <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>EGFP-Cre-ERT2</sup> mice by crossing <italic>Pgd</italic><sup>fl/fl</sup> mice with <italic>Foxp3</italic><sup>EGFP-Cre-ERT2</sup> mice (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1H</xref>). In these mice, expression of Cre in <italic>Foxp3</italic> promoter is induced by tamoxifen treatment and EGFP can be used as a detection marker (<xref ref-type="bibr" rid="bib20">Rubtsov et al., 2010</xref>). Suppressive function of targeted Tregs was evaluated in vitro and in vivo in a tumor model. In 6-week-old <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>EGFP-Cre-ERT2</sup> mice, tamoxifen was injected on days 0, 1, and 3 to induce deletion of 6PGD in Tregs. To induce tumor formation, B16F10 melanoma cells were injected into the flank region of the mice on day 10 post tamoxifen treatment (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). Although the tamoxifen induction does not induce deletion in 100% of Tregs in vivo, this model would induce sufficient 6PGD deletion in targeted Tregs to be tracked in vivo (<xref ref-type="bibr" rid="bib20">Rubtsov et al., 2010</xref>). <italic>Foxp3</italic> expression was detected by <italic>EGFP</italic> expression (CD4<sup>+</sup>CD25<sup>+</sup>EGFP<sup>+</sup> cells in spleen) (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). EGFP<sup>+</sup> sorted cells showed reduced suppressive activity in vitro (<xref ref-type="fig" rid="fig3">Figure 3H</xref>), as seen in the YFP<sup>+</sup> sorted cells from <italic>Pgd</italic><sup>fl/fl</sup> <italic>Foxp3</italic><sup>Cre</sup> mice (<xref ref-type="fig" rid="fig2">Figure 2H–I</xref>) or Tregs generated in presence of 6-AN (<xref ref-type="fig" rid="fig3">Figure 3D–E</xref>).</p><p>In the B16F10 tumor model, induced 6PGD deletion in Tregs resulted in reduced tumor growth (<xref ref-type="fig" rid="fig3">Figure 3I</xref>) and smaller final mass (<xref ref-type="fig" rid="fig3">Figure 3J</xref>) on day 16 post tumor induction. Assessing cell types in the tumor, we saw more CD8<sup>+</sup> and CD4<sup>+</sup> T cell infiltration (<xref ref-type="fig" rid="fig3">Figure 3K–L</xref>), along with higher IFN-γ production from both CD4<sup>+</sup> (<xref ref-type="fig" rid="fig3">Figure 3M</xref>) and CD8<sup>+</sup> (<xref ref-type="fig" rid="fig3">Figure 3N</xref>) T cells in <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>EGFP-Cre-ERT2</sup> versus WT mice. Thus, in the tumor microenvironment, Tregs were altered by 6PGD blockade to unleash host anti-tumor responses. As such, 6PGD can serve as a metabolic checkpoint for immune activation by modulating Tregs activity, which is considered to be desirable (<xref ref-type="bibr" rid="bib25">Wang et al., 2017</xref>; <xref ref-type="bibr" rid="bib17">Pacella and Piconese, 2019</xref>).</p></sec><sec id="s2-4"><title>6PGD function in Tregs is required for control of allergic (Th2) responses</title><p>Tregs are responsible for suppression of T subset effector responses but they also have the plasticity to convert into these subsets (<xref ref-type="bibr" rid="bib21">Shi and Chi, 2019</xref>). A well-defined organ to follow Th2 responses control by Tregs is lung. In <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice, significant Th2 (allergic) responses were evident in the lung (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). These included higher collagen deposits (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>, top panels), higher mucus accumulation (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>, bottom panels), and higher infiltration of T cells (both CD4<sup>+</sup> and CD8<sup>+</sup> cells) in the lung (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>) with enhanced production of Th2 markers such as IL-13 (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>), IL-5 (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1F</xref>), and IL-4 (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1H</xref>) by CD4<sup>+</sup> T cells. The sorted YFP<sup>+</sup> Tregs from 6PGD blocked mice also expressed lower levels of <italic>Foxp3</italic> and higher levels of <italic>Gata3</italic> transcription factors (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). Moreover, the Th2 markers were higher in the spleen of the <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>,G,I).</p><p>High allergic responses in <italic>Pgd</italic><sup>fl/fl</sup> <italic>Foxp3</italic><sup>Cre</sup> mice was also evident with higher infiltration of eosinophils (CD11c<sup>low/-</sup> Siglect-F<sup>+</sup>) in the lung (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1J</xref>; <xref ref-type="bibr" rid="bib23">Stevens et al., 2007</xref>) and spleen (CD11b<sup>+</sup> Siglect-F<sup>+</sup>) (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1K</xref>; <xref ref-type="bibr" rid="bib8">Hey et al., 2015</xref>). These allergic responses were accompanied by infiltration of CD11b<sup>+</sup> Ly6G<sup>+</sup> cells in the lung and spleen of <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1L-M</xref>; <xref ref-type="bibr" rid="bib29">Xue et al., 2020</xref>; <xref ref-type="bibr" rid="bib1">Bronte et al., 2016</xref>).</p><p>Although the shift toward Th2 responses (Figures: 1M; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B-C</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>; <xref ref-type="fig" rid="fig2">Figure 2G</xref>; and <xref ref-type="fig" rid="fig3">Figure 3C</xref>) was dominant in 6PGD-deficient Tregs, enhancement of Th1 and Th17 responses was also noted by higher IFN-γ and IL-17A in the serum (<xref ref-type="fig" rid="fig1">Figure 1M</xref>) and higher frequency of CD4<sup>+</sup>IFN-γ<sup>+</sup> and CD4<sup>+</sup>IL-17A<sup>+</sup> cells in the spleen (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E, G</xref>). Beside these enhanced Th1 and Th17 responses, YFP<sup>+</sup> Tregs isolated from <italic>Pgd</italic><sup>fl/fl</sup> <italic>Foxp3</italic><sup>Cre</sup> mice showed elevated expression of <italic>Ifng</italic>, <italic>Tbx21,</italic> and <italic>Il17a</italic> genes (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A, C</xref>) and sorted Tregs cultured in vitro secreted higher amount of IFN-γ and IL-17A into media (<xref ref-type="fig" rid="fig2">Figure 2G</xref>).</p><p>In other reports, comparable patterns of Treg plasticity have been observed by blocking a key regulator of Tregs metabolism, mTOR. <italic>Mtor</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice showed 10- to 15-fold increases of Th2 mediators while increases in Th1 and Th17 responses were 2- to 3-fold (<xref ref-type="bibr" rid="bib2">Chapman et al., 2018</xref>).</p></sec><sec id="s2-5"><title>6PGD blockade in Tregs induces metabolic reprogramming similar to that of T effector cells</title><p>Next, we examined metabolic shifts in the Tregs isolated from WT and <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice. It should be noted that the pro-inflammatory microenvironment of the mice could contribute to Tregs metabolic reprogramming, beside the intrinsic effects of 6PGD. We first assessed glycolysis and mitochondrial respiration by measuring the extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) (<xref ref-type="fig" rid="fig4">Figure 4A–B</xref>). Tregs isolated from <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice showed significant increase in both basal and reserve capacity in ECAR (<xref ref-type="fig" rid="fig4">Figure 4A</xref>) and OCR (<xref ref-type="fig" rid="fig4">Figure 4B</xref>) compared to WT Tregs. We also evaluated Glc uptake and mitochondrial status by fluorescent dye staining (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Compared to WT Tregs, 6PGD-deficient Tregs had increased Glc uptake capacity determined by 2-NBDG uptake (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). These cells also showed increase in mitochondrial potential (ΔΨm) as measured by TMRE (<xref ref-type="fig" rid="fig4">Figure 4C</xref>) without changes in the mitochondrial mass as examined by MitoTracker Deep Red FM (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Moreover, mitochondrial ROS (assessed by MitoSox Red) was enhanced in 6PGD blocked Tregs (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). These results are consistent with the observed skew of the Tregs phenotype and markers toward conventional CD4<sup>+</sup> T effector subsets (<xref ref-type="bibr" rid="bib13">Michalek et al., 2011</xref>; <xref ref-type="bibr" rid="bib16">Pacella et al., 2018</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Blocking 6-phosphogluconate dehydrogenase (6PGD) in regulatory T cells (Tregs) induces reprogramming of glycolysis, mitochondrial respiration, and non-oxidative pentose phosphate pathway (PPP).</title><p>(<bold>A–B</bold>) Extracellular acidification and oxygen consumption analysis on YFP<sup>+</sup> sorted cells from <italic>Pgd</italic><sup>fl/fl</sup> <italic>Foxp3</italic><sup>Cre</sup> and wild-type (WT) mice was performed using Seahorse XF24 metabolic analyzer as described in supplemental information. The extracellular acidification rate (ECAR) (<bold>A</bold>) and oxygen consumption rate (OCR) (<bold>B</bold>) are shown (N = 4). (<bold>C</bold>) YFP<sup>+</sup> cells glucose (Glc) uptake capacity was determined by 2-NBDG uptake, mitochondrial potential (ΔΨm) by TMRE, mitochondrial mass by MitoTracker Deep Red FM and mitochondrial ROS by MitoSox Red. Results are representative of three independent experiments with N = 4 per group. (<bold>D</bold>) YFP<sup>+</sup> cells were sorted from WT and <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice and cultured in the presence of IL-2 (700 IU/ml) and anti-CD3/anti-CD28 coated beads (Treg:beads ratio 1:3) plus D<sub>7</sub>-Glc and <sup>13</sup>C<sub>5</sub>,<sup>15</sup>N<sub>2</sub>-glutamine (Gln) for 48 hr. Isotope labeling patterns of metabolites of cell extracts were analyzed by IC-UHRMS. Data shown demonstrates D<sub>7</sub>-Glc and <sup>13</sup>C<sub>5</sub>,<sup>15</sup>N<sub>2</sub>-Gln incorporation into the PPP metabolites via non-oxidative PPP and gluconeogenesis. Results were generated with N = 2. Legend in X-axis D* = sum of D<sub>1</sub> to D<sub>x</sub> or Glc-derived species; C* = sum of <sup>13</sup>C<sub>1</sub> to <sup>13</sup>C<sub>x</sub> or Gln-derived species; C*D* = sum of dual <sup>13</sup>C<sub>1</sub> to <sup>13</sup>C<sub>x</sub> and D<sub>1</sub> to D<sub>x</sub> or Glc and Gln-derived species; G6P, glucose-6-phosphate; 6PG, 6-phosphogluconate; R5P, ribose-5-phosphate; S7P, sedoheptulose-7-phosphate; Gly3P, glyceraldehyde-3-phosphate; X5P, xylulose-5-phosphate; E4P, erythrose-4-phosphate; F6P, fructose-6-phosphate; OAA, oxaloacetate; PEP, phosphoenolpyruvate.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67476-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Glycolysis, Krebs cycle, and nucleotide biosynthesis are enhanced in 6-phosphogluconate dehydrogenase (6PGD)-deficient Tregs.</title><p>(<bold>A–C</bold>) The same cell extracts as in <xref ref-type="fig" rid="fig4">Figure 4</xref> were analyzed for metabolites of glycolysis (<bold>A</bold>), the Krebs cycle (<bold>B</bold>), and nucleotide biosynthesis (<bold>C</bold>) by IC-UHRFTMS. Legend in X-axis: D* = sum of D<sub>1</sub> to D<sub>x</sub> or Glc-derived species; C* = sum of <sup>13</sup>C<sub>1</sub> to <sup>13</sup>C<sub>x</sub> or Gln-derived species; C*D* = sum of dual <sup>13</sup>C<sub>1</sub> to <sup>13</sup>C<sub>x</sub> and D<sub>1</sub> to D<sub>x</sub> or Glc and Gln-derived species; C*NxDx = sum of triply labeled (<sup>13</sup>C<sub>1</sub> to <sup>13</sup>C<sub>x</sub>, D<sub>1</sub> to D<sub>x</sub>, and <sup>15</sup>N<sub>1</sub> to <sup>15</sup>N<sub>x</sub>) species. X is ≥1 for each metabolite isotopologue. Abbreviations used are: F1,6BP: fructose-1,6-bisphosphate; 2,3PG: 2,3-diphosphoglycerate; αKG: α-ketoglutarate; OAA: oxaloacetate; UTP: uridine triphosphate; CTP: cytidine triphosphate; GTP: guanosine triphosphate; ATP: adenosine triphosphate.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67476-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Pentose phosphate pathway (PPP) pathway reprogramming in 6-phosphogluconate dehydrogenase (6PGD)-deficient regulatory T cells (Tregs) generated in vitro.</title><p>Wild-type (WT) and <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> naïve CD4<sup>+</sup> T cells were differentiated into Tregs (as inducible Tregs [iTreg]) in the presence of IL-2+ TGF-β for 4 days, in vitro. In last 48 hr of polarization D<sub>7</sub>-glucose (Glc) and <sup>13</sup>C<sub>5</sub>,<sup>15</sup>N<sub>2</sub>-glutamine (Gln) were replaced in the media. Isotope labeling patterns of metabolites of cell extracts were analyzed by IC-UHRMS. Data shown demonstrates D<sub>7</sub>-Glc and <sup>13</sup>C<sub>5</sub>,<sup>15</sup>N<sub>2</sub>-Gln incorporation into the PPP metabolites via non-oxidative PPP and gluconeogenesis. Results were generated with N = 2. Abbreviations are the same as <xref ref-type="fig" rid="fig4">Figure 4</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67476-fig4-figsupp2-v1.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Glycolysis, Krebs cycle, and nucleotide biosynthesis reprogramming in 6-phosphogluconate dehydrogenase (6PGD)-deficient Tregs generated in vitro.</title><p>(<bold>A–C</bold>) The same cell extracts as in <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref> were analyzed for metabolites of glycolysis (<bold>A</bold>), the Krebs cycle (<bold>B</bold>), and nucleotide biosynthesis (<bold>C</bold>) by IC-UHRFTMS. These results were from in vitro generated Tregs as inducible Tregs (iTreg). Legend and abbreviations are the same as <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67476-fig4-figsupp3-v1.tif"/></fig></fig-group><p>During transition from naïve CD4<sup>+</sup> T cells, Tregs switch from Glc utilization to other fuel sources such as fatty acids (<xref ref-type="bibr" rid="bib18">Procaccini et al., 2016</xref>; <xref ref-type="bibr" rid="bib12">Macintyre et al., 2014</xref>), which could help sustain their function in low Glc conditions such as in the tumor microenvironment. Glutamine (Gln) is an important fuel source for T cells that is consumed in mitochondria. However, it has been shown that deficiency of the glutamine transporter ASCT2 did not impact Tregs generation (<xref ref-type="bibr" rid="bib14">Nakaya et al., 2014</xref>), which raises the question of the importance of Gln metabolism in Tregs.</p><p>Based on these observations, we tracked simultaneously Glc and Gln metabolism in WT and <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> Tregs, both as direct isolates from mouse models with inflammatory disorder and also Tregs generated from naïve CD4<sup>+</sup> T cells in vitro. In the first set, YFP<sup>+</sup> Tregs were sorted from WT and <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice and cultured in the presence of IL-2 (700 IU/ml) and anti-CD3/anti-CD28 coated beads (Treg:beads ratio 1:3) plus D<sub>7</sub>-Glc and <sup>13</sup>C<sub>5</sub>,<sup>15</sup>N<sub>2</sub>-Gln for 48 hr. In the second set, naïve CD4<sup>+</sup> from WT and <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice were polarized with IL-2+ TGF-β for 4 days and the medium was changed to that containing D<sub>7</sub>-Glc + <sup>13</sup>C<sub>5</sub>,<sup>15</sup>N<sub>2</sub>-Gln for the last 48 hr. Transformations of D<sub>7</sub>-Glc and <sup>13</sup>C<sub>5</sub><sup>15</sup>N<sub>2</sub>-Gln in sorted Tregs into metabolites of PPP/gluconeogenesis (GNG) (<xref ref-type="fig" rid="fig4">Figure 4D</xref>), glycolysis (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>), Krebs cycle (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>), and the nucleotide synthesis pathway (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>) were determined by SIRM analysis. Shift in the same metabolic pathways examined in in vitro generated Tregs is presented in <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref> and <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>.</p><p>SIRM analysis showed higher buildup of D-labeled glycolytic intermediates (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>), which together with enhanced ECAR (<xref ref-type="fig" rid="fig4">Figure 4A</xref>) pointed to increased glycolytic capacity in 6PGD blocked Tregs. These cells also displayed increased levels of D and/or <sup>13</sup>C-labeled Krebs cycle metabolites (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>), which together with the observed increased OCR and mitochondrial potential (<xref ref-type="fig" rid="fig4">Figure 4B–C</xref>) indicated elevated Krebs cycle activity. Notably, Gln served as the main fuel source for the Krebs cycle (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>), with Gln metabolism being significantly higher in 6PGD-deficient than WT Tregs. Enhanced Gln metabolism via the Krebs cycle led to increased αKG production (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B-F</xref>), which could serve as critical ‘metabolic signal’ for CD4<sup>+</sup> T subset differentiation (<xref ref-type="bibr" rid="bib11">Klysz et al., 2015</xref>). αKG level has been shown to control methylation of the <italic>Foxp3</italic> gene locus resulting in a shift of balance between Treg/Th1 (<xref ref-type="bibr" rid="bib11">Klysz et al., 2015</xref>) and Treg/Th17 (<xref ref-type="bibr" rid="bib28">Xu et al., 2017</xref>). Whether such epigenetic metabolic mechanism is involved in skewing 6PGD blocked Tregs toward Teff subsets awaits further investigation.</p></sec><sec id="s2-6"><title>6PGD deficiency in Tregs enhances non-oxidative PPP and GNG</title><p>SIRM analysis also showed that 6PGD-deficient Tregs extensively accumulated G6P and 6PG (<xref ref-type="fig" rid="fig4">Figure 4D–a and b</xref>), which confirmed effective blockade of oxidative PPP at 6PGD (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). However, instead of depletion, this blockade led to enhanced accumulation of D and/or <sup>13</sup>C-labeled R5P (<xref ref-type="fig" rid="fig4">Figure 4D–c</xref>), which are downstream products of the 6PGD reaction. Also D and/or <sup>13</sup>C-labeled sedoheptulose-7-phosphate (S7P) (<xref ref-type="fig" rid="fig4">Figure 4D–d</xref>), erythrose-4-phosphate (<xref ref-type="fig" rid="fig4">Figure 4D–e</xref>), and fructose-6-phosphate (F6P) (<xref ref-type="fig" rid="fig4">Figure 4D–f</xref>) accumulated in 6PGD-deficient Tregs. These metabolites are all products of the non-oxidative PPP. These results point to enhanced non-oxidative PPP that results in elevated production of R5P from D<sub>7</sub>-Glc and <sup>13</sup>C<sub>5</sub>,<sup>15</sup>N<sub>2</sub>-Gln (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>), despite the blockade at 6PGD. In turn, R5P generated fueled the enhanced biosynthesis of both pyrimidine and purine nucleotides (D, <sup>13</sup>C, and <sup>15</sup>N labeled species, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>) to fulfill the nucleotide demands of activated T cells.</p><p>It should be noted that enhanced incorporation of Gln derived carbon (C* or D*C*/C*NxDx scrambled species) into 6PG (C* and D*C* scrambled species, <xref ref-type="fig" rid="fig4">Figure 4D–b</xref>) and ATP/GTP (C*, D*C*, and C*NxDx, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C-m,l</xref>) in 6PGD-deficient Tregs are consistent with elevated GNG in these cells. This is because these <sup>13</sup>C-labeled species can only be produced via the reaction sequence of glutaminolysis, the Krebs cycle, and GNG initiated by conversion of OAA to PEP via PEPCK, followed by the reversal of the glycolytic reactions. The latter produce 3-phosphoglycerate, glyceraldehyde-3-phosphate, F6P, and G6P, which can fuel both oxidative and non-oxidative PPP as well as serine biosynthesis-one carbon pathway to power purine biosynthesis (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). Increased accumulation of <sup>13</sup>C-G6P, together with that of D-G6P (<xref ref-type="fig" rid="fig4">Figure 4D–a</xref>) indicate enhanced activity of G6PD, the first rate-limiting and NADPH-producing enzyme of the oxidative branch of the PPP. This is expected to help compensate for the loss of NADPH production due to blocked 6PGD action. Overall, similar shifts of metabolic patterns in Tregs generated in vitro (iTregs in <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref> and <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>) as those sorted from mouse models were evident.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In our pilot studies, we found that inhibition of G6PD led to reduced T cell survival with little changes in IFN-γ production (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B-C</xref>) but that of 6PGD resulted in higher T cell survival and T subsets activations (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B-C,I-J</xref> ). Our G6PD inhibitor study is consistent with a recent study, which showed that G6PD inhibition depleted NADPH and decreased inflammatory cytokine production by T cells (<xref ref-type="bibr" rid="bib7">Ghergurovich et al., 2020</xref>). To better understand the role of 6PGD in T cells, we generated <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice to examine the effect of 6GPD blockade on Tregs as central immune regulators. Interestingly, <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice showed severe autoimmune disorders highlighting a critical role of 6PGD in Tregs function (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Tregs isolated from <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice showed reduced suppressive function in vitro and in vivo (<xref ref-type="fig" rid="fig2">Figure 2</xref>), which was accompanied by a shift of gene expression signatures and phenotype markers toward T CD4<sup>+</sup> subsets of Th1, Th2, and Th17. Loss of suppressive function and plasticity toward conventional subsets was also reproduced by treatments with 6PGD small molecule inhibitor 6-AN (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p><p>Although Glc, but not Gln, contributes to Tregs differentiation and function (<xref ref-type="bibr" rid="bib16">Pacella et al., 2018</xref>; <xref ref-type="bibr" rid="bib18">Procaccini et al., 2016</xref>; <xref ref-type="bibr" rid="bib14">Nakaya et al., 2014</xref>), Glc depletion by blocking the Glc transporter Glut1 did not alter the suppressive function of Tregs (<xref ref-type="bibr" rid="bib13">Michalek et al., 2011</xref>; <xref ref-type="bibr" rid="bib12">Macintyre et al., 2014</xref>). However, our study showed that the suppressive function of Tregs was modulated by altered Glc metabolism via the oxidative PPP, that is, <italic>6PGD</italic> deficiency in Tregs resulting in significantly improved anti-tumor responses (<xref ref-type="fig" rid="fig3">Figure 3F–N</xref>) or changed IBD outcomes (<xref ref-type="fig" rid="fig2">Figure 2</xref>). This qualifies 6PGD as an immune checkpoint by modulating the Treg function while implicating the importance of Glc metabolism via the oxidative PPP in Treg activation.</p><p>As our knowledge of Glc and Gln metabolism in Tregs is limited, we tracked the metabolic fates of both fuel substrates with stable isotope tracers in 6PGD blocked versus WT Tregs. We found that blocking 6PGD in oxidative PPP shifted Glc flow into glycolysis and non-oxidative PPP to provide sufficient substrates (e.g. one-carbon metabolites and R5P) for fueling nucleotide biosynthesis (<xref ref-type="fig" rid="fig4">Figure 4</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). This was also accompanied by enhanced Gln flow into GNG to power nucleobase synthesis and NADPH production, which can compensate for NADPH loss due to 6PGD blockade. These reprogrammed metabolic activities co-occurred with the shift of expression in phenotypic and functional markers toward conventional T CD4<sup>+</sup> subsets. The importance of glycolytic shift on modulating Tregs fitness has been shown in previous studies (<xref ref-type="bibr" rid="bib26">Watson et al., 2021</xref>; <xref ref-type="bibr" rid="bib31">Zappasodi et al., 2021</xref>). Tregs in high Glc environment lose their fitness while upregulation of lactate metabolism is important for maintaining their suppressive phenotype (<xref ref-type="bibr" rid="bib26">Watson et al., 2021</xref>). Also, the presence of Glc was shown to be a key factor in interfering Treg function under anti-CTLA-4 treatment (<xref ref-type="bibr" rid="bib31">Zappasodi et al., 2021</xref>). Moreover, although glycolysis is key to supporting the energy and anabolic demands during Treg expansion (<xref ref-type="bibr" rid="bib16">Pacella et al., 2018</xref>; <xref ref-type="bibr" rid="bib4">De Rosa et al., 2015</xref>), further increase in glycolysis as a result of mTOR and c-Myc activation suppresses Treg generation (<xref ref-type="bibr" rid="bib9">Kabat et al., 2016</xref>; <xref ref-type="bibr" rid="bib27">Wei et al., 2016</xref>). Our metabolic fate analysis not only corroborates with glycolytic control of Treg functions but also reveals the role of 6PGD as a key regulator of Treg stability.</p><p>Although disruption of Gln uptake did not impact Treg function (<xref ref-type="bibr" rid="bib14">Nakaya et al., 2014</xref>), enhanced Gln metabolism in 6PGD-deficient Tregs was evident and co-occurred with the shift from Treg to Th1 (<xref ref-type="bibr" rid="bib13">Michalek et al., 2011</xref>; <xref ref-type="bibr" rid="bib11">Klysz et al., 2015</xref>), Th2 (<xref ref-type="bibr" rid="bib13">Michalek et al., 2011</xref>), or Th17 (<xref ref-type="bibr" rid="bib13">Michalek et al., 2011</xref>; <xref ref-type="bibr" rid="bib28">Xu et al., 2017</xref>) phenotypes. Increased Gln oxidation in the Krebs cycle promoted the synthesis of immunomodulatory metabolites such as αKG (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>), which has been shown to signal Foxp3 suppression (<xref ref-type="bibr" rid="bib11">Klysz et al., 2015</xref>; <xref ref-type="bibr" rid="bib28">Xu et al., 2017</xref>). At the same time, diversion of Gln carbons for enhanced nucleotide synthesis would help meet the metabolic demand of the shift toward conventional T subsets. Thus, Gln metabolism could synergize with 6PGD deficiency in eliciting Treg plasticity toward immune activation. Further studies will be required to substantiate such metabolic mechanism.</p><p>In summary, we reported a critical role of 6PGD, the second rate-limiting enzyme of PPP, in skewing Tregs function and metabolism toward those of the Th1, Th2, and Th17 subsets. As such, 6PGD could be a novel metabolic target in clinical applications such as autoimmune disorders or cancer therapies.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD3ε-PerCP (clone: 145–2 C11); (Armenian hamster monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#100326; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_893317">AB_893317</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD4-APC (clone: GK1.5); (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#100412; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312697">AB_312697</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD4-PE (clone: GK1.5); (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#100408; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312693">AB_312693</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD4-Pacific Blue (clone: GK1.5); (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#100428; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_">AB_</ext-link> 493,647</td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD8a-FITC (clone: 53–6.7); (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#100706; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312745">AB_312745</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD8a-Pacific Blue(clone: 53–6.7); (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#100725; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_493425">AB_493425</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD25-BV711 (clone: PC61); (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#102049; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2564130">AB_2564130</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD11b-Pacific Blue (clone: M1/70); (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#101224; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_755986">AB_755986</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD11c-PE-Cy7 (clone: N418); (Armenian hamster monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#117318; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_493568">AB_493568</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD25-PE-Cy7 (clone: PC61); (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#102016; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_312865">AB_312865</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD40L-APC (clone: MR1); (Armenian hamster monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#106510; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2561561">AB_2561561</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD44-PE-Cy7 (clone: IM7); (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#103030; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_830787">AB_830787</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD45.2-PE-Cy7 (clone: 104); (mouse monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#109830; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1186098">AB_1186098</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD71-APC (clone: RI7217); (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#113820; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2728135">AB_2728135</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD98-PE-Cy7 (clone: RL388); (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#128214; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2750547">AB_2750547</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD45.2-PerCP (clone: 104); (mouse monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#109826; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_893349">AB_893349</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD62L-Pacific Blue (clone: MEL-14); (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#104424; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_493380">AB_493380</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD69-PE (clone: H1.2F3); (Armenian hamster monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#104508; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_313111">AB_313111</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD107a-APC-Cy7 (clone: 1D4B); (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#121616; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10643268">AB_10643268</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse Foxp3-PE (clone: MF-14); (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#126404; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1089117">AB_1089117</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse siglec-F (CD170)-APC (clone: S17007L); (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#155508; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2750237">AB_2750237</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse Ly6C-APC (clone: HK1.4); (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#128016; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1732076">AB_1732076</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse Ly6G-PE (clone: 1A8); (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#127608; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1186099">AB_1186099</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse IL-4-PE (clone: 11B11); (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#504104; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_315318">AB_315318</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse IL-5-APC (clone: TRFK5); (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#504306; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_315330">AB_315330</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse IL-13-PE (clone: eBio13A); (rat monoclonal)</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No# 12-7133-82; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_763559">AB_763559</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse IL-17A-PE (clone: eBio17B7); (rat monoclonal)</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No#12-7177-81; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_763582">AB_763582</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse IFN-γ-APC (clone: XMG1.2); (rat monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#505810; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_315404">AB_315404</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse Granzyme B-PE (clone: NGZB); (rat monoclonal)</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No#12-8898-82; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10870787">AB_10870787</ext-link></td><td align="left" valign="bottom">FACS (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD3ε-Purified (clone: 145–2 C11); (Armenian hamster monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#100340; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_11149115">AB_11149115</ext-link></td><td align="left" valign="bottom">Culture (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse CD28-Purified (clone: 37.51); (Syrian hamster monoclonal)</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#102116; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_11147170">AB_11147170</ext-link></td><td align="left" valign="bottom">Culture (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-mouse 6PGD; (rabbit polyclonal)</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="left" valign="bottom">Cat No#HPA031314; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10610278">AB_10610278</ext-link></td><td align="left" valign="bottom">Western blot (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-β-actin (D6A8); (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat No#8457; RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10950489">AB_10950489</ext-link></td><td align="left" valign="bottom">Western blot (1:1000)</td></tr><tr><td align="left" valign="bottom">Genetic reagent (species)</td><td align="left" valign="bottom"><italic>Pgd</italic> TaqMan Assay probe (FAM-MGB) (mouse)</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No#4351372; Assay ID:Mm01263703_m1</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Genetic reagent (species)</td><td align="left" valign="bottom"><italic>Foxp3</italic> TaqMan Assay probe (FAM-MGB) (mouse)</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No#4331182; Assay ID: Mm00475162_m1</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Genetic reagent (species)</td><td align="left" valign="bottom">Gata3 TaqMan Assay probe (FAM-MGB) (mouse)</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No#4331182; Assay ID:Mm00484683_m1</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Genetic reagent (species)</td><td align="left" valign="bottom"><italic>Il5</italic> TaqMan Assay probe (FAM-MGB) (mouse)</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No#4331182; Assay ID:Mm00439646_m1</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Genetic reagent (species)</td><td align="left" valign="bottom"><italic>Il13</italic> TaqMan Assay probe (FAM-MGB) (mouse)</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No#4331182; Assay ID: Mm00434204_m1</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Genetic reagent (species)</td><td align="left" valign="bottom"><italic>Ifng</italic> TaqMan Assay probe (FAM-MGB) (mouse)</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No#4331182; Assay ID: Mm01168134_m1</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Genetic reagent (species)</td><td align="left" valign="bottom"><italic>Tbet</italic> (<italic>Tbx21</italic>) TaqMan Assay probe (FAM-MGB) (mouse)</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No# 4331182; Assay ID: Mm00450960_m1</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Genetic reagent (species)</td><td align="left" valign="bottom"><italic>Il17a</italic> TaqMan Assay probe (FAM-MGB) (mouse)</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No#4331182; Assay ID: Mm00439618_m1</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Genetic reagent (species)</td><td align="left" valign="bottom"><italic>Icos</italic> TaqMan Assay probe (FAM-MGB)</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No#4331182; Assay ID: Mm00497600_m1</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Genetic reagent (species)</td><td align="left" valign="bottom"><italic>Il4</italic> TaqMan Assay probe (FAM-MGB) (mouse)</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No#4331182; Assay ID:Mm00445259_m1</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Genetic reagent</td><td align="left" valign="bottom"><italic>Il10</italic> TaqMan Assay probe (FAM-MGB) (mouse)</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No#4331182; Assay ID: Mm00439614_m1</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Genetic reagent (species)</td><td align="left" valign="bottom"><italic>Batf3</italic> TaqMan Assay probe (FAM-MGB) (mouse)</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No#4331182; Assay ID: Mm01318274_m1</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Genetic reagent (species)</td><td align="left" valign="bottom"><italic>Hey1</italic> TaqMan Assay probe (FAM-MGB) (mouse)</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No#4331182; Assay ID: Mm00468865_m1</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Genetic reagent (species)</td><td align="left" valign="bottom"><italic>Bcl6</italic> TaqMan Assay probe (FAM-MGB) (mouse)</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No#4331182; Assay ID: Mm00477633_m1</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Genetic reagent (species)</td><td align="left" valign="bottom"><italic>Gzb</italic> TaqMan Assay probe (FAM-MGB) (mouse)</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No#4331182; Assay ID: Mm00442834_m1</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Genetic reagent (species)</td><td align="left" valign="bottom">18 S rRNA TaqMan Assay probe (VIC-MGB) (mouse)</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No#4319413E</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Cell line (species)</td><td align="left" valign="bottom">B16-F10 (mouse)</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">ATCC CRL-6475; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0159">CVCL_0159</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">6-Aminonicotinamide (6-AN)</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="left" valign="bottom">Cat No#A68203</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Tamoxifen</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="left" valign="bottom">Cat No#T5648-1G</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Dehydroepiandrosterone (DHEA)</td><td align="left" valign="bottom">Cayman Chemical</td><td align="left" valign="bottom">Cat No#15728</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Dimethyl sulfoxide (DMSO)</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="left" valign="bottom">Cat No#D2438</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Tetra-methylrhodamine ester (TMRE)</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No#T669</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">MitoSOX Red</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No#M36008</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">MitoTracker Deep Red FM</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No#M22426</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">2-NBD-glucose (2-NBDG)</td><td align="left" valign="bottom">Cayman Chemical</td><td align="left" valign="bottom">Cat No#11046</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">D-GLUCOSE (1,2,3,4,5,6,6-D7, 97–98%)</td><td align="left" valign="bottom">Cambridge Isotope laboratories</td><td align="left" valign="bottom">Cat No#DLM-2062-PK</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom"><sup>13</sup>C<sub>5</sub>,<sup>15</sup>N<sub>2</sub>-Glutamine</td><td align="left" valign="bottom">Cambridge Isotope laboratories</td><td align="left" valign="bottom">Cat No#CNLM-1275-H-PK</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Fetal bovine serum, heat inactivated</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No#16140071</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">NuPAGE 4–12%, Bis-Tris, 1.5 mm, Mini Protein Gel</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No#NP0335BOX</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">NuPAGE MES SDS Running Buffer</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No#NP0002</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Recombinant Mouse IL-2</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#575404</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Recombinant Mouse TGF-β1</td><td align="left" valign="bottom">BioLegend</td><td align="left" valign="bottom">Cat No#763104</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Milliplex MAP Mouse Cytokine/Chemokine Magnetic Bead Panel – Premixed 32 Plex</td><td align="left" valign="bottom">Millipore</td><td align="left" valign="bottom">Cat No# MCYTMAG-70K-PX32</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Mouse Ig Isotyping Array Q1</td><td align="left" valign="bottom">RayBiotech</td><td align="left" valign="bottom">Cat No#QAM-ISO-1–2</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">CellTrace CFSE Cell Proliferation Kit</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No#C34554</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Dynabeads Mouse T-Activator CD3/CD28</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No#11456D</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Fixation/Permeabilization Solution Kit with BD GolgiPlug</td><td align="left" valign="bottom">BD Bioscience</td><td align="left" valign="bottom">Cat No#555028</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">eBioscience Foxp3/ Transcription Factor Staining Buffer Set</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No#00-5523-00</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Aqua)</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No#L34957</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">EasySep Mouse CD4+ T Cell Isolation Kit</td><td align="left" valign="bottom">STEMCELL Technologies</td><td align="left" valign="bottom">Cat No#19852RF</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">EasySep Mouse Naïve CD4+ T Cell Isolation Kit</td><td align="left" valign="bottom">STEMCELL Technologies</td><td align="left" valign="bottom">Cat No#19765</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">EasySep Mouse CD4+ CD25+ Regulatory T Cell Isolation Kit II</td><td align="left" valign="bottom">STEMCELL Technologies</td><td align="left" valign="bottom">Cat No#18783</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">RNeasy Mini Kit</td><td align="left" valign="bottom">Qiagen</td><td align="left" valign="bottom">Cat No#74104</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Seahorse XF Cell Mito Stress Test Kit</td><td align="left" valign="bottom">Agilent</td><td align="left" valign="bottom">Cat No#103015–100</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Pierce BCA Protein Assay Kit</td><td align="left" valign="bottom">ThermoFisher</td><td align="left" valign="bottom">Cat No#23225</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Genetic reagent(<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Pgd</italic>fl/fl <italic>Foxp3</italic>YFP-Cre</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"><italic>6PGD</italic> exon 5 floxed. Send reagent request to <ext-link ext-link-type="uri" xlink:href="http://pseth@bidmc.harvard.edu/">pseth@bidmc.harvard.edu</ext-link></td></tr><tr><td align="left" valign="bottom">Genetic reagent(<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">C57BL/6 J (B6 CD45.2+)</td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="left" valign="bottom">Stock No: 000664</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Genetic reagent(<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">B6.SJL-Ptprca Pepcb/BoyJ (B6 CD45.1+)</td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="left" valign="bottom">Stock No: 002014 | B6 Cd45.1</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Genetic reagent(<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">B6.129S7-Rag1<sup>tm1Mom</sup>/J</td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="left" valign="bottom">Stock No: 002216</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Genetic reagent(<italic>Mus musculus</italic>)</td><td align="left" valign="bottom">B6.129(Cg)-<italic>Foxp3</italic><sup>tm4(YFP/icre)Ayr</sup>/J</td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="left" valign="bottom">Stock No: 016959</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Genetic reagent(<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Foxp3</italic><sup>tm9(EGFP/cre/ERT2)Ayr</sup>/J</td><td align="left" valign="bottom">The Jackson Laboratory</td><td align="left" valign="bottom">Stock No: 016961</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">FlowJo_V10</td><td align="left" valign="bottom">FlowJo</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.flowjo.com/">https://www.flowjo.com/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_008520">SCR_008520</ext-link></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad Prism_V6</td><td align="left" valign="bottom">GraphPad</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/">https://www.graphpad.com/</ext-link>; RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002798">SCR_002798</ext-link></td><td align="left" valign="bottom"> </td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cell line</title><p>B16-F10 cell line was obtained from ATCC (ATCC CRL-6475). The cell line was tested for <italic>Mycoplasma</italic> contamination.</p></sec><sec id="s4-2"><title>Mice</title><p>Steps to generate of <italic>Pgd</italic><sup>fl/fl</sup><italic>Cd4</italic><sup>Cre</sup>, <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup>, and <italic>Pgd</italic><sup>fl/fl</sup> <italic>Foxp3</italic><sup>EGFP-Cre-ERT2</sup> mice are described in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>. Verification of 6PGD deletion was done by PCR, western blot, and alteration in metabolite profile associated with the enzyme. Other mice used during experiments including C57BL/6 J (B6 CD45.2<sup>+</sup>), B6.SJL-Ptprca Pepcb/BoyJ (B6 CD45.1<sup>+</sup>), B6.129(Cg)-<italic>Foxp3</italic><sup>tm4(YFP/icre)Ayr</sup>/J (<italic>Foxp3</italic><sup>YFP-cre</sup>), <italic>Foxp3</italic><sup>tm9(EGFP/cre/ERT2)Ayr</sup>/J (<italic>Foxp3</italic><sup>eGFP-Cre-ERT2</sup>), and B6.129S7-<italic>Rag1</italic><sup>tm1Mom</sup>/J (<italic>Rag1</italic><sup>-/-</sup>) mice were purchased from Jackson Laboratories. All mice were kept in specific pathogen-free conditions prior to use. Animal work was done in accordance with the Institutional Animal Care and Use Committee of the University of BIDMC (Protocol number 040–2016).</p></sec><sec id="s4-3"><title>Detection of cells markers by flow cytometry</title><p>Flow cytometry stainings were done on prepared cells. Cells from spleen and lymph nodes were obtained by tissue harvest, mechanically disintegration, passing through 70 μm cell strainer and then red blood cell lysis. Tumor infiltration cells were also prepared using the same steps with additional 30 min collagenase treatment at 37°C. Cultured cells and sorted cells just passed one step of wash with FACS buffer (PBS containing 1% FBS). Cells were suspended in FACS buffer and stained for surface markers for 30 min at 4°C. Aqua LIVE/DEAD Fixable Dead Cell Stain was used in all staining to distinguish dead cells. Intracellular staining for IL-4, IL-13, Il-5, IFN-γ, IL-17A, TGF-β, and granzyme B was performed with the Fixation/Permeabilization Solution Kit with BD GolgiPlug (BD Bioscience) according to the manufacturer’s protocol. To detect cytokines, cells were cultured in RMPI containing 10% FBS and were stimulated with PMA (50 ng/ml), ionomycin (1 μg/ml), and GolgiPlug (1 μl/ml) for 4 hr at 37C before starting the staining. For assessment of Foxp3, cells were stained intracellularly using the Foxp3/Transcription Factor Buffer Set (eBiosciences) following the manufacturer’s protocol. Glc uptake was analyzed by incubation of the cells with 20 μM 2-NBD-Glc (Cayman Chemical) for 30 min at 37°C. Cells were analyzed by a CytoFLEX LX (Beckman Coulter) cytometer and analysis was performed using FlowJo_V10 software. All antibodies are listed in the Key resources table.</p></sec><sec id="s4-4"><title>Cell isolation by flow cytometry cell sorting</title><p>To obtain purified cells, single cells were first enriched by negative selection using EasySep Mouse CD4<sup>+</sup> T cells isolation kit (STEMCELL Technologies) following manufacturer’s protocols. Then cells were stained for desired surface markers and sorted by flow cytometry. Surface markers for gating/sorting of each cell type included: naïve CD4<sup>+</sup> T cells (CD4<sup>+</sup> CD62L<sup>high</sup> CD44<sup>low</sup>), YFP<sup>+</sup> Tregs (CD4<sup>+</sup> CD25<sup>+</sup> YFP<sup>+</sup>), EFGP<sup>+</sup> Tregs (CD4<sup>+</sup> CD25<sup>+</sup> EGFP<sup>+</sup>), and T effector cells (CD4<sup>+</sup> CD45RB<sup>high</sup>). All the stainings were done at 4°C for 30 min and sorting was done by Becton Dickinson SORP FACSAria II (Beckman Coulter). Isolated cell phenotypes were confirmed by running again with flow cytometer (CytoFLEX LX, Beckman Coulter).</p></sec><sec id="s4-5"><title>Cell culture and treatment</title><sec id="s4-5-1"><title>Naïve CD4<sup>+</sup> T cell treatment with inhibitors</title><p>Naïve CD4<sup>+</sup> T cells (CD4<sup>+</sup> CD62L<sup>high</sup> CD44<sup>low</sup>) were isolated and cultured in complete RPMI media containing 10% FBS and IL-2 (20 IU/ml) and treated with 6-AN (10 µM), DHEA (10 µM), or vehicle DMSO. Cells stimulation was done by adding soluble anti-CD3 (1 µg/ml) and soluble anti-CD28 (1 µg/ml). Cells were harvested and evaluated 4 days post culture.</p></sec><sec id="s4-5-2"><title>Naïve CD4<sup>+</sup> T cells polarization toward Tregs and treatment with 6-AN</title><p>To target 6PGD in vitro, naïve CD4<sup>+</sup> T cells (CD4<sup>+</sup> CD62L<sup>high</sup> CD44<sup>low</sup>) were isolated and polarized to Tregs using IL-2 (50 IU/ml) and TGF-β1 (5 ng/ml). Stimulation was done by culturing the cells in plate coated antibodies. For coating anti-CD3 and anti-CD28 (2 µg/ml PBS each) were put on the plate and incubated 4 hr at 37°C and then washed twice with PBS. For inhibitor treatment 6-AN (10 µM) or vehicle DMSO was added.</p></sec><sec id="s4-5-3"><title>Culture of YFP<sup>+</sup> sorted cells</title><p>Isolated Tregs (CD4<sup>+</sup> CD25<sup>+</sup> YFP<sup>+</sup>) were cultured in vitro in presence of IL-2 (700 IU/ml) and anti-CD3/anti-CD28 coated beads (Treg:beads ratio 1:3) and cells number was assessed at 24 and 48 hr time points. Media was evaluated for cytokines production.</p></sec></sec><sec id="s4-6"><title>Suppression assay</title><p>Suppression assay was done on prepared Tregs as YFP<sup>+</sup> sorted cells from <italic>6PGD</italic><sup>+/+</sup><italic>Foxp3</italic><sup>Cre</sup> (WT) and <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice, EGFP<sup>+</sup> sorted cells from <italic>Pgd</italic><sup>+/+</sup> <italic>Foxp3</italic><sup>EGFP-Cre-ERT2</sup> (WT) and <italic>Pgd</italic><sup>fl/fl</sup> <italic>Foxp3</italic><sup>EGFP-Cre-ERT2</sup> mice, and also DMSO (control) and 6-AN derived Tregs. These cells express CD45.2 on their surface (B6 CD45.2<sup>+</sup>). To check suppressive capacity of prepared Tregs, the cells were mixed with WT CD45.1<sup>+</sup> effector T cells (CD4<sup>+</sup> CD45RB<sup>high</sup>) in different ratio and cultured in U shaped plate. The effecter cells were stained with CFSE (0.5 mM) for 30 min before culture. For optimized stimulation of effector cells, 2.5 × 10<sup>5</sup> irradiated (30 Gy) splenocytes from CD45.2<sup>+</sup> mice (WT B6 CD45.2<sup>+</sup>) and soluble anti-CD3 (1 µg/ml) was added. After 72 hr of co-culture, amount of CFSE dilution was determined in CD4<sup>+</sup> CD45.1<sup>+</sup> effector cells using flow cytometer (CytoFLEX LX, Beckman Coulter).</p></sec><sec id="s4-7"><title>RNA purification, RNAseq, and real-time quantitative PCR</title><p>Total RNA was extracted from YFP<sup>+</sup> sorted cells with RNeasy Mini Kit (Qiagen) and RNA concentrations were determined using Nanodrop (Thermo Scientific). Total DNA-free RNA was used for mRNA isolation and library construction. Libraries were sequenced on an Illumina HISEQ 2500 (Illumina). Confirmation of RNAseq was done by examination of key representative genes by real-time quantitative PCR method using ABI 7300 Real-Time PCR system (Applied Biosystems). Used TaqMan probes are listed in the Key resources table. Expression of each gene was normalized to the housekeeping gene expression (18 S rRNA) as ΔCT = CT (gene X) – CT (18 S rRNA). The alteration between groups was calculated as fold change = 2^(ΔΔCT). ΔΔCT is: CT (gene X) – CT (gene X at baseline).</p></sec><sec id="s4-8"><title>Bioenergetics analysis by Seahorse and mitochondrial activity</title><p>Prepared Tregs (YFP<sup>+</sup> sorted cells) were seeded on Cell-Tak coated Seahorse XFe24 (Agilent) culture plates (0.8–1 × 10<sup>6</sup> cells/well) in assay media. The media was DMEM supplemented with 1% BSA and 25 mM Glc, 1 mM pyruvate, and 2 mM Gln. The ECAR and OCR were measured over 75 min. To obtain maximal respiratory and control values, cells were treated with oligomycin (1 μM), FCCP (1.5 μM), and rotenone/antimycin A (0.5 μM).</p><p>Mitochondrial activity also was examined by flow cytometry. For this, cells were stained with 200 nM MitoTracker Deep Red FM (ThermoFisher) for mitochondrial mass and 200 nM tetra-methylrhodamine ester (TMRE) (ThermoFisher) for mitochondrial membrane potential. Staining was done in FACS buffer (PBS containing 2% FBS) along with cell surface markers for 30 min at 37°C. To detect mitochondrial reactive oxygen species cells surface markers were added and then 5 μM MitoSOX Red (ThermoFisher) was added in last 10 min incubation at 37°C. Cells were analyzed by a CytoFLEX LX (Beckman Coulter) cytometer and analyzed by FlowJo_V10.</p></sec><sec id="s4-9"><title>IBD model</title><p>To examine Tregs suppressive activities in vivo, the IBD model was used as described previously (<xref ref-type="bibr" rid="bib15">Ostanin et al., 2009</xref>; <xref ref-type="bibr" rid="bib22">Steinbach et al., 2015</xref>). In brief, YFP<sup>+</sup> cells from WT and <italic>Pgd<sup>fl/fl</sup> Foxp3<sup>Cre</sup></italic> mice and also CD4<sup>+</sup> effector T cells (CD4<sup>+</sup>CD45RB<sup>high</sup>) from WT mice were sorted and mixed. Cells were resuspended to 4 × 10<sup>6</sup> cells/ml effector (CD45<sup>high</sup>) and 2 × 10<sup>6</sup> cells/ml Treg (YFP<sup>+</sup>). Total of 4 × 10<sup>5</sup> CD45<sup>high</sup> and 2 × 10<sup>5</sup> Treg was injected into each <italic>Rag1</italic><sup>-/-</sup> (B6.129S7-<italic>Rag1</italic><sup>tm1Mom</sup>/J) mice intra-peritoneally (i.p.). Control positive group was injection of effector cells alone and negative control group was <italic>Rag1</italic><sup>-/-</sup> mice without injection. Disease progress was monitored by weight loss, change in stools form, and diarrhea. Colons length and thickness along with colon’s histochemistry were evaluated 45 days post cells injection.</p></sec><sec id="s4-10"><title>SIRM analysis on Tregs</title><p>To trace Glc and Gln in Tregs, YFP<sup>+</sup> sorted cells from WT and <italic>Pgd</italic><sup>fl/fl</sup><italic>Foxp3</italic><sup>Cre</sup> mice were cultured in presence of IL-2 (700 IU/ml) and anti-CD3/anti-CD28 coated beads (Treg:beads ratio 1:3) and D<sub>7</sub>-Glc plus <sup>13</sup>C<sub>5</sub>,<sup>15</sup>N<sub>2</sub>-Gln for 48 hr. To prepare labeling media, Glc-free Gln-free RPMI medium was supplemented with 10% dialyzed FBS (Life Technologies), 20 mM HEPES, 0.05 mM 2-mercaptoethanol, and 1% penicillin-streptomycin. Isotope labeling patterns of metabolites of cell extracts were analyzed by Ion Chromatography-UltraHigh Resolution Mass Spectrometry. The procedures were followed as previously described (<xref ref-type="bibr" rid="bib6">Fan et al., 2016b</xref>; <xref ref-type="bibr" rid="bib5">Fan et al., 2016a</xref>).</p></sec><sec id="s4-11"><title>Statistical analysis</title><p>All the statistical analyses were done using GraphPad Prism 6 (GraphPad) and Excel software. Difference between groups was analyzed using the Student’s t test (for two groups) or one-way ANOVA (for multiple groups), followed by the post hoc Tukey test. Differences in tumor growth was calculated by two-way ANOVA. Differences between groups were rated significant at values of p &lt; 0.05. In the figures all data are shown as mean ± SEM and *p ≤ 0.05, <italic>**</italic>p ≤ 0.01, <italic>***</italic>p ≤ 0.001.</p></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Experimental design and execution, Mouse models and immunological designs and analysis, Metabolic pathway interpretation, Formal analysis, Investigation, Methodology, Project administration, Visualization, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Investigation, SIRM analyses</p></fn><fn fn-type="con" id="con3"><p>Data curation, Investigation, SIRM design and analyses</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Contributed to SIRM experimental design and execution, Metabolic pathway interpretation, Data curation, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Data curation, Funding acquisition, Investigation, Methodology, Resources, Supervision, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal work was done in accordance with the Institutional Animal Care and Use Committee of Beth Israel Deaconess Medical Center.(Protocol number 040-2016).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-67476-transrepform1-v1.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>RNAseq data was deposited to NCBI BioSample (BioSample Accession # PRJNA706901).</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Daneshmandi</surname><given-names>S</given-names></name><name><surname>Cassel</surname><given-names>T</given-names></name><name><surname>Higashi</surname><given-names>RH</given-names></name><name><surname>Fan</surname><given-names>TWM</given-names></name><name><surname>Seth</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>6-Phosphogluconate dehydrogenase (6PGD) a key checkpoint in reprogramming of Treg metabolism and function</data-title><source>NCBI Sequence Read Archive</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/sra/PRJNA706901">PRJNA706901</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was supported by BIDMC seed funds to PS, 2014-07-1112 target grant from Bayer to PS, and a pilot grant to PS from 1U24DK097215-01A1 (to RMH and TWMF), and the Markey Cancer Center Redox and Metabolism Shared Resource Facility P30CA177558.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bronte</surname><given-names>V</given-names></name><name><surname>Brandau</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>SH</given-names></name><name><surname>Colombo</surname><given-names>MP</given-names></name><name><surname>Frey</surname><given-names>AB</given-names></name><name><surname>Greten</surname><given-names>TF</given-names></name><name><surname>Mandruzzato</surname><given-names>S</given-names></name><name><surname>Murray</surname><given-names>PJ</given-names></name><name><surname>Ochoa</surname><given-names>A</given-names></name><name><surname>Ostrand-Rosenberg</surname><given-names>S</given-names></name><name><surname>Rodriguez</surname><given-names>PC</given-names></name><name><surname>Sica</surname><given-names>A</given-names></name><name><surname>Umansky</surname><given-names>V</given-names></name><name><surname>Vonderheide</surname><given-names>RH</given-names></name><name><surname>Gabrilovich</surname><given-names>DI</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>12150</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms12150</pub-id><pub-id pub-id-type="pmid">27381735</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chapman</surname><given-names>NM</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Nguyen</surname><given-names>TLM</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Vogel</surname><given-names>P</given-names></name><name><surname>Dhungana</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Neale</surname><given-names>G</given-names></name><name><surname>Locasale</surname><given-names>JW</given-names></name><name><surname>Chi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>mTOR coordinates transcriptional programs and mitochondrial metabolism of activated Treg subsets to protect tissue homeostasis</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>2095</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-04392-5</pub-id><pub-id pub-id-type="pmid">29844370</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>LH</given-names></name><name><surname>Kauffman</surname><given-names>FC</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Metabolism via the pentose phosphate pathway in rat pheochromocytoma PC12 cells: effects of nerve growth factor and 6-aminonicotinamide</article-title><source>Neurochemical Research</source><volume>12</volume><fpage>521</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1007/BF01000236</pub-id><pub-id pub-id-type="pmid">2955240</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Rosa</surname><given-names>V</given-names></name><name><surname>Galgani</surname><given-names>M</given-names></name><name><surname>Porcellini</surname><given-names>A</given-names></name><name><surname>Colamatteo</surname><given-names>A</given-names></name><name><surname>Santopaolo</surname><given-names>M</given-names></name><name><surname>Zuchegna</surname><given-names>C</given-names></name><name><surname>Romano</surname><given-names>A</given-names></name><name><surname>De Simone</surname><given-names>S</given-names></name><name><surname>Procaccini</surname><given-names>C</given-names></name><name><surname>La Rocca</surname><given-names>C</given-names></name><name><surname>Carrieri</surname><given-names>PB</given-names></name><name><surname>Maniscalco</surname><given-names>GT</given-names></name><name><surname>Salvetti</surname><given-names>M</given-names></name><name><surname>Buscarinu</surname><given-names>MC</given-names></name><name><surname>Franzese</surname><given-names>A</given-names></name><name><surname>Mozzillo</surname><given-names>E</given-names></name><name><surname>La Cava</surname><given-names>A</given-names></name><name><surname>Matarese</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants</article-title><source>Nature Immunology</source><volume>16</volume><fpage>1174</fpage><lpage>1184</lpage><pub-id pub-id-type="doi">10.1038/ni.3269</pub-id><pub-id pub-id-type="pmid">26414764</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>Twm</given-names></name><name><surname>Lane</surname><given-names>AN</given-names></name><name><surname>Higashi</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2016">2016a</year><article-title>Stable Isotope Resolved Metabolomics Studies in Ex Vivo TIssue Slices</article-title><source>Bio-Protocol</source><volume>6</volume><elocation-id>e1730</elocation-id><pub-id pub-id-type="doi">10.21769/bioprotoc.1730</pub-id><pub-id pub-id-type="pmid">27158639</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>Twm</given-names></name><name><surname>Warmoes</surname><given-names>MO</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Turchan-Cholewo</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>JT</given-names></name><name><surname>Mahan</surname><given-names>A</given-names></name><name><surname>Higashi</surname><given-names>RM</given-names></name><name><surname>Lane</surname><given-names>AN</given-names></name></person-group><year iso-8601-date="2016">2016b</year><article-title>Distinctly perturbed metabolic networks underlie differential tumor tissue damages induced by immune modulator β-glucan in a two-case ex vivo non-small-cell lung cancer study</article-title><source>Cold Spring Harbor Molecular Case Studies</source><volume>2</volume><elocation-id>a000893</elocation-id><pub-id pub-id-type="doi">10.1101/mcs.a000893</pub-id><pub-id pub-id-type="pmid">27551682</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghergurovich</surname><given-names>JM</given-names></name><name><surname>García-Cañaveras</surname><given-names>JC</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Schmidt</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>TeSlaa</surname><given-names>T</given-names></name><name><surname>Patel</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Britt</surname><given-names>EC</given-names></name><name><surname>Piqueras-Nebot</surname><given-names>M</given-names></name><name><surname>Gomez-Cabrera</surname><given-names>MC</given-names></name><name><surname>Lahoz</surname><given-names>A</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Beier</surname><given-names>UH</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Rabinowitz</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A small molecule G6PD inhibitor reveals immune dependence on pentose phosphate pathway</article-title><source>Nature Chemical Biology</source><volume>16</volume><fpage>731</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.1038/s41589-020-0533-x</pub-id><pub-id pub-id-type="pmid">32393898</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hey</surname><given-names>YY</given-names></name><name><surname>Tan</surname><given-names>JKH</given-names></name><name><surname>O’Neill</surname><given-names>HC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Redefining Myeloid Cell Subsets in Murine Spleen</article-title><source>Frontiers in Immunology</source><volume>6</volume><elocation-id>652</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2015.00652</pub-id><pub-id pub-id-type="pmid">26793192</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kabat</surname><given-names>AM</given-names></name><name><surname>Harrison</surname><given-names>OJ</given-names></name><name><surname>Riffelmacher</surname><given-names>T</given-names></name><name><surname>Moghaddam</surname><given-names>AE</given-names></name><name><surname>Pearson</surname><given-names>CF</given-names></name><name><surname>Laing</surname><given-names>A</given-names></name><name><surname>Abeler-Dörner</surname><given-names>L</given-names></name><name><surname>Forman</surname><given-names>SP</given-names></name><name><surname>Grencis</surname><given-names>RK</given-names></name><name><surname>Sattentau</surname><given-names>Q</given-names></name><name><surname>Simon</surname><given-names>AK</given-names></name><name><surname>Pott</surname><given-names>J</given-names></name><name><surname>Maloy</surname><given-names>KJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The autophagy gene Atg16l1 differentially regulates Treg and TH2 cells to control intestinal inflammation</article-title><source>eLife</source><volume>5</volume><elocation-id>e12444</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.12444</pub-id><pub-id pub-id-type="pmid">26910010</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>AP</given-names></name><name><surname>Finlay</surname><given-names>DK</given-names></name><name><surname>Hinton</surname><given-names>HJ</given-names></name><name><surname>Clarke</surname><given-names>RG</given-names></name><name><surname>Fiorini</surname><given-names>E</given-names></name><name><surname>Radtke</surname><given-names>F</given-names></name><name><surname>Cantrell</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Notch-induced T cell development requires phosphoinositide-dependent kinase 1</article-title><source>The EMBO Journal</source><volume>26</volume><fpage>3441</fpage><lpage>3450</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7601761</pub-id><pub-id pub-id-type="pmid">17599070</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klysz</surname><given-names>D</given-names></name><name><surname>Tai</surname><given-names>X</given-names></name><name><surname>Robert</surname><given-names>PA</given-names></name><name><surname>Craveiro</surname><given-names>M</given-names></name><name><surname>Cretenet</surname><given-names>G</given-names></name><name><surname>Oburoglu</surname><given-names>L</given-names></name><name><surname>Mongellaz</surname><given-names>C</given-names></name><name><surname>Floess</surname><given-names>S</given-names></name><name><surname>Fritz</surname><given-names>V</given-names></name><name><surname>Matias</surname><given-names>MI</given-names></name><name><surname>Yong</surname><given-names>C</given-names></name><name><surname>Surh</surname><given-names>N</given-names></name><name><surname>Marie</surname><given-names>JC</given-names></name><name><surname>Huehn</surname><given-names>J</given-names></name><name><surname>Zimmermann</surname><given-names>V</given-names></name><name><surname>Kinet</surname><given-names>S</given-names></name><name><surname>Dardalhon</surname><given-names>V</given-names></name><name><surname>Taylor</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Glutamine-dependent α-ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation</article-title><source>Science Signaling</source><volume>8</volume><elocation-id>ra97</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aab2610</pub-id><pub-id pub-id-type="pmid">26420908</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macintyre</surname><given-names>AN</given-names></name><name><surname>Gerriets</surname><given-names>VA</given-names></name><name><surname>Nichols</surname><given-names>AG</given-names></name><name><surname>Michalek</surname><given-names>RD</given-names></name><name><surname>Rudolph</surname><given-names>MC</given-names></name><name><surname>Deoliveira</surname><given-names>D</given-names></name><name><surname>Anderson</surname><given-names>SM</given-names></name><name><surname>Abel</surname><given-names>ED</given-names></name><name><surname>Chen</surname><given-names>BJ</given-names></name><name><surname>Hale</surname><given-names>LP</given-names></name><name><surname>Rathmell</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function</article-title><source>Cell Metabolism</source><volume>20</volume><fpage>61</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2014.05.004</pub-id><pub-id pub-id-type="pmid">24930970</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michalek</surname><given-names>RD</given-names></name><name><surname>Gerriets</surname><given-names>VA</given-names></name><name><surname>Jacobs</surname><given-names>SR</given-names></name><name><surname>Macintyre</surname><given-names>AN</given-names></name><name><surname>MacIver</surname><given-names>NJ</given-names></name><name><surname>Mason</surname><given-names>EF</given-names></name><name><surname>Sullivan</surname><given-names>SA</given-names></name><name><surname>Nichols</surname><given-names>AG</given-names></name><name><surname>Rathmell</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets</article-title><source>Journal of Immunology</source><volume>186</volume><fpage>3299</fpage><lpage>3303</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1003613</pub-id><pub-id pub-id-type="pmid">21317389</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakaya</surname><given-names>M</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Chang</surname><given-names>J-H</given-names></name><name><surname>Chang</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Blonska</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>S-C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation</article-title><source>Immunity</source><volume>40</volume><fpage>692</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2014.04.007</pub-id><pub-id pub-id-type="pmid">24792914</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostanin</surname><given-names>DV</given-names></name><name><surname>Bao</surname><given-names>J</given-names></name><name><surname>Koboziev</surname><given-names>I</given-names></name><name><surname>Gray</surname><given-names>L</given-names></name><name><surname>Robinson-Jackson</surname><given-names>SA</given-names></name><name><surname>Kosloski-Davidson</surname><given-names>M</given-names></name><name><surname>Price</surname><given-names>VH</given-names></name><name><surname>Grisham</surname><given-names>MB</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade</article-title><source>American Journal of Physiology. Gastrointestinal and Liver Physiology</source><volume>296</volume><fpage>G135</fpage><lpage>G146</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.90462.2008</pub-id><pub-id pub-id-type="pmid">19033538</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pacella</surname><given-names>I</given-names></name><name><surname>Procaccini</surname><given-names>C</given-names></name><name><surname>Focaccetti</surname><given-names>C</given-names></name><name><surname>Miacci</surname><given-names>S</given-names></name><name><surname>Timperi</surname><given-names>E</given-names></name><name><surname>Faicchia</surname><given-names>D</given-names></name><name><surname>Severa</surname><given-names>M</given-names></name><name><surname>Rizzo</surname><given-names>F</given-names></name><name><surname>Coccia</surname><given-names>EM</given-names></name><name><surname>Bonacina</surname><given-names>F</given-names></name><name><surname>Mitro</surname><given-names>N</given-names></name><name><surname>Norata</surname><given-names>GD</given-names></name><name><surname>Rossetti</surname><given-names>G</given-names></name><name><surname>Ranzani</surname><given-names>V</given-names></name><name><surname>Pagani</surname><given-names>M</given-names></name><name><surname>Giorda</surname><given-names>E</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Matarese</surname><given-names>G</given-names></name><name><surname>Barnaba</surname><given-names>V</given-names></name><name><surname>Piconese</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth</article-title><source>PNAS</source><volume>115</volume><fpage>E6546</fpage><lpage>E6555</lpage><pub-id pub-id-type="doi">10.1073/pnas.1720113115</pub-id><pub-id pub-id-type="pmid">29941600</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pacella</surname><given-names>I</given-names></name><name><surname>Piconese</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Immunometabolic Checkpoints of Treg Dynamics: Adaptation to Microenvironmental Opportunities and Challenges</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>1889</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.01889</pub-id><pub-id pub-id-type="pmid">31507585</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Procaccini</surname><given-names>C</given-names></name><name><surname>Carbone</surname><given-names>F</given-names></name><name><surname>Di Silvestre</surname><given-names>D</given-names></name><name><surname>Brambilla</surname><given-names>F</given-names></name><name><surname>De Rosa</surname><given-names>V</given-names></name><name><surname>Galgani</surname><given-names>M</given-names></name><name><surname>Faicchia</surname><given-names>D</given-names></name><name><surname>Marone</surname><given-names>G</given-names></name><name><surname>Tramontano</surname><given-names>D</given-names></name><name><surname>Corona</surname><given-names>M</given-names></name><name><surname>Alviggi</surname><given-names>C</given-names></name><name><surname>Porcellini</surname><given-names>A</given-names></name><name><surname>La Cava</surname><given-names>A</given-names></name><name><surname>Mauri</surname><given-names>P</given-names></name><name><surname>Matarese</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The Proteomic Landscape of Human Ex Vivo Regulatory and Conventional T Cells Reveals Specific Metabolic Requirements</article-title><source>Immunity</source><volume>44</volume><elocation-id>712</elocation-id><pub-id pub-id-type="doi">10.1016/j.immuni.2016.02.022</pub-id><pub-id pub-id-type="pmid">28843073</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubtsov</surname><given-names>YP</given-names></name><name><surname>Rasmussen</surname><given-names>JP</given-names></name><name><surname>Chi</surname><given-names>EY</given-names></name><name><surname>Fontenot</surname><given-names>J</given-names></name><name><surname>Castelli</surname><given-names>L</given-names></name><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Treuting</surname><given-names>P</given-names></name><name><surname>Siewe</surname><given-names>L</given-names></name><name><surname>Roers</surname><given-names>A</given-names></name><name><surname>Henderson</surname><given-names>WR</given-names></name><name><surname>Muller</surname><given-names>W</given-names></name><name><surname>Rudensky</surname><given-names>AY</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces</article-title><source>Immunity</source><volume>28</volume><fpage>546</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2008.02.017</pub-id><pub-id pub-id-type="pmid">18387831</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubtsov</surname><given-names>YP</given-names></name><name><surname>Niec</surname><given-names>RE</given-names></name><name><surname>Josefowicz</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Darce</surname><given-names>J</given-names></name><name><surname>Mathis</surname><given-names>D</given-names></name><name><surname>Benoist</surname><given-names>C</given-names></name><name><surname>Rudensky</surname><given-names>AY</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Stability of the regulatory T cell lineage in vivo</article-title><source>Science</source><volume>329</volume><fpage>1667</fpage><lpage>1671</lpage><pub-id pub-id-type="doi">10.1126/science.1191996</pub-id><pub-id pub-id-type="pmid">20929851</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Chi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Metabolic Control of Treg Cell Stability, Plasticity, and Tissue-Specific Heterogeneity</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>2716</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.02716</pub-id><pub-id pub-id-type="pmid">31921097</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinbach</surname><given-names>EC</given-names></name><name><surname>Gipson</surname><given-names>GR</given-names></name><name><surname>Sheikh</surname><given-names>SZ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+ CD45RB high T Cells into Immunodeficient Mice</article-title><source>Journal of Visualized Experiments</source><volume>2015</volume><elocation-id>98</elocation-id><pub-id pub-id-type="doi">10.3791/52533</pub-id><pub-id pub-id-type="pmid">25938395</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>WW</given-names></name><name><surname>Kim</surname><given-names>TS</given-names></name><name><surname>Pujanauski</surname><given-names>LM</given-names></name><name><surname>Hao</surname><given-names>X</given-names></name><name><surname>Braciale</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Detection and quantitation of eosinophils in the murine respiratory tract by flow cytometry</article-title><source>Journal of Immunological Methods</source><volume>327</volume><fpage>63</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2007.07.011</pub-id><pub-id pub-id-type="pmid">17716680</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Timilshina</surname><given-names>M</given-names></name><name><surname>You</surname><given-names>Z</given-names></name><name><surname>Lacher</surname><given-names>SM</given-names></name><name><surname>Acharya</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Kang</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>J-A</given-names></name><name><surname>Chang</surname><given-names>HW</given-names></name><name><surname>Kim</surname><given-names>K-J</given-names></name><name><surname>Park</surname><given-names>B</given-names></name><name><surname>Song</surname><given-names>J-H</given-names></name><name><surname>Ko</surname><given-names>H-J</given-names></name><name><surname>Park</surname><given-names>Y-Y</given-names></name><name><surname>Ma</surname><given-names>M-J</given-names></name><name><surname>Nepal</surname><given-names>MR</given-names></name><name><surname>Jeong</surname><given-names>TC</given-names></name><name><surname>Chung</surname><given-names>Y</given-names></name><name><surname>Waisman</surname><given-names>A</given-names></name><name><surname>Chang</surname><given-names>J-H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Activation of Mevalonate Pathway via LKB1 Is Essential for Stability of Treg Cells</article-title><source>Cell Reports</source><volume>27</volume><fpage>2948</fpage><lpage>2961</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.05.020</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Franco</surname><given-names>F</given-names></name><name><surname>Ho</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy</article-title><source>Trends in Cancer</source><volume>3</volume><fpage>583</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2017.06.005</pub-id><pub-id pub-id-type="pmid">28780935</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>MJ</given-names></name><name><surname>Vignali</surname><given-names>PDA</given-names></name><name><surname>Mullett</surname><given-names>SJ</given-names></name><name><surname>Overacre-Delgoffe</surname><given-names>AE</given-names></name><name><surname>Peralta</surname><given-names>RM</given-names></name><name><surname>Grebinoski</surname><given-names>S</given-names></name><name><surname>Menk</surname><given-names>AV</given-names></name><name><surname>Rittenhouse</surname><given-names>NL</given-names></name><name><surname>DePeaux</surname><given-names>K</given-names></name><name><surname>Whetstone</surname><given-names>RD</given-names></name><name><surname>Vignali</surname><given-names>DAA</given-names></name><name><surname>Hand</surname><given-names>TW</given-names></name><name><surname>Poholek</surname><given-names>AC</given-names></name><name><surname>Morrison</surname><given-names>BM</given-names></name><name><surname>Rothstein</surname><given-names>JD</given-names></name><name><surname>Wendell</surname><given-names>SG</given-names></name><name><surname>Delgoffe</surname><given-names>GM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Metabolic support of tumour-infiltrating regulatory T cells by lactic acid</article-title><source>Nature</source><volume>591</volume><fpage>645</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-03045-2</pub-id><pub-id pub-id-type="pmid">33589820</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Long</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Guy</surname><given-names>C</given-names></name><name><surname>Shrestha</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Vogel</surname><given-names>P</given-names></name><name><surname>Neale</surname><given-names>G</given-names></name><name><surname>Green</surname><given-names>DR</given-names></name><name><surname>Chi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Autophagy enforces functional integrity of regulatory T cells by coupling environmental cues and metabolic homeostasis</article-title><source>Nature Immunology</source><volume>17</volume><fpage>277</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1038/ni.3365</pub-id><pub-id pub-id-type="pmid">26808230</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>T</given-names></name><name><surname>Stewart</surname><given-names>KM</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Xie</surname><given-names>M</given-names></name><name><surname>Ryu</surname><given-names>JK</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Ma</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Ni</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>N</given-names></name><name><surname>Zhu</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Akassoglou</surname><given-names>K</given-names></name><name><surname>Dong</surname><given-names>C</given-names></name><name><surname>Driggers</surname><given-names>EM</given-names></name><name><surname>Ding</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Metabolic control of TH17 and induced Treg cell balance by an epigenetic mechanism</article-title><source>Nature</source><volume>548</volume><fpage>228</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1038/nature23475</pub-id><pub-id pub-id-type="pmid">28783731</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>L</given-names></name><name><surname>Shan</surname><given-names>W</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Feng</surname><given-names>D</given-names></name><name><surname>Lv</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Elevated granulocytic myeloid-derived suppressor cells are closely related with elevation of Th17 cells in mice with experimental asthma</article-title><source>Ternational Journal of Biological Sciences</source><volume>16</volume><fpage>2072</fpage><lpage>2083</lpage><pub-id pub-id-type="doi">10.7150/ijbs.43596</pub-id><pub-id pub-id-type="pmid">32549755</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Blanco</surname><given-names>DB</given-names></name><name><surname>Neale</surname><given-names>G</given-names></name><name><surname>Vogel</surname><given-names>P</given-names></name><name><surname>Avila</surname><given-names>J</given-names></name><name><surname>Clish</surname><given-names>CB</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Shrestha</surname><given-names>S</given-names></name><name><surname>Rankin</surname><given-names>S</given-names></name><name><surname>Long</surname><given-names>L</given-names></name><name><surname>Kc</surname><given-names>A</given-names></name><name><surname>Chi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Homeostatic control of metabolic and functional fitness of Treg cells by LKB1 signalling</article-title><source>Nature</source><volume>548</volume><fpage>602</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1038/nature23665</pub-id><pub-id pub-id-type="pmid">28847007</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zappasodi</surname><given-names>R</given-names></name><name><surname>Serganova</surname><given-names>I</given-names></name><name><surname>Cohen</surname><given-names>IJ</given-names></name><name><surname>Maeda</surname><given-names>M</given-names></name><name><surname>Shindo</surname><given-names>M</given-names></name><name><surname>Senbabaoglu</surname><given-names>Y</given-names></name><name><surname>Watson</surname><given-names>MJ</given-names></name><name><surname>Leftin</surname><given-names>A</given-names></name><name><surname>Maniyar</surname><given-names>R</given-names></name><name><surname>Verma</surname><given-names>S</given-names></name><name><surname>Lubin</surname><given-names>M</given-names></name><name><surname>Ko</surname><given-names>M</given-names></name><name><surname>Mane</surname><given-names>MM</given-names></name><name><surname>Zhong</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Ghosh</surname><given-names>A</given-names></name><name><surname>Abu-Akeel</surname><given-names>M</given-names></name><name><surname>Ackerstaff</surname><given-names>E</given-names></name><name><surname>Koutcher</surname><given-names>JA</given-names></name><name><surname>Ho</surname><given-names>P-C</given-names></name><name><surname>Delgoffe</surname><given-names>GM</given-names></name><name><surname>Blasberg</surname><given-names>R</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Merghoub</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours</article-title><source>Nature</source><volume>591</volume><fpage>652</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03326-4</pub-id><pub-id pub-id-type="pmid">33588426</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Cloer</surname><given-names>C</given-names></name><name><surname>Neale</surname><given-names>G</given-names></name><name><surname>Vogel</surname><given-names>P</given-names></name><name><surname>Chi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function</article-title><source>Nature</source><volume>499</volume><fpage>485</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1038/nature12297</pub-id><pub-id pub-id-type="pmid">23812589</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.67476.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Sarin</surname><given-names>Apurva</given-names></name><role>Reviewing Editor</role><aff><institution>Institute for Stem Cell Science and Regenerative Medicine</institution><country>India</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Sarin</surname><given-names>Apurva</given-names></name><role>Reviewer</role><aff><institution>Institute for Stem Cell Science and Regenerative Medicine</institution><country>India</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Piconese</surname><given-names>Silvia</given-names></name><role>Reviewer</role></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>The study by Daneshmandi et al, advances knowledge of immune-metabolism, describing a key role for the pentose phosphate pathway in the expression of the transcription factor Foxp3, and functional consequences in a cell type that regulates prolonged inflammation in the mammalian immune system. Using a combination of in vitro and in vivo analysis and multiple approaches, included the detailed analysis of metabolic pathways, the study identifies a metabolic checkpoint in immune cell differentiation and function. The study will be of interest to immunologists, cell biologists and those with interests in metabolic networks underpinning cellular differentiation and function.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;6-Phosphogluconate dehydrogenase (6PGD) a key checkpoint in reprogramming of Treg metabolism and function&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Apurva Sarin as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Satyajit Rath as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Silvia Piconese (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Summary:</p><p>This study demonstrates that 6PGD, a rate-limiting enzyme in the oxidative pentose-phosphate pathway, modulates Treg metabolism and functions. Mice with a Treg-restricted 6PGD deficiency (either constitutive or inducible) spontaneously develop a multi-organ scurfy-like lethal disease, and succumb to early death, suggesting a loss of Treg cell immunosuppressive function. Treg cell frequency in these mice is apparently only slightly reduced and is mostly affected by a transcriptional reprogramming to resemble that of conventional T effector subsets, with Tregs presenting skewed metabolism toward glycolysis, Krebs cycle, and non-oxidative PPP. The study includes a description of disease phenotypes and cellular properties, which is supported by transcriptional analysis and detailed metabolite analysis at the cellular level. The precise mechanism through which 6PGD destabilizes Tregs remains to be elucidated. The core ideas of this manuscript are of interest in the area of Treg immunometabolism, which currently lags behind conventional CD4 and CD8 literature.</p><p>Daneshmandi et al. describe metabolic and functional consequences of blocking the oxidative pentose phosphate pathway (PPP) in Treg cells. While the core ideas of this manuscript are of interest in the area of Treg immunometabolism, there are substantial issues – outlined in the comments, that remain to be addressed.</p><p>Essential revisions:</p><p>1. Most experiments describing the Treg cell phenotype and function are in Foxp3Cre 6PGDfl/fl mice, which has significant systemic inflammation. This confounds Treg cell phenotypes that are presented (e.g., RNA-seq profile, in vitro suppression, ECAR, OCR, adoptive transfer). The Foxp3Cre 6PGDfl/fl system is appropriate for the in vivo profiling data of conventional CD4, CD8, and Treg cells, but not to conclude direct effects of 6PGD loss within Treg cells. The characterization of 6PGD deficient Treg cells should be undertaken in an inflammation-free system, using either mixed bone marrow chimera mice or an inducible-cre system (see the following comment). Alternatively, key analyses may be performed using Foxp3Cre/+ heterozygous females, only if they do not develop inflammation. Characterization of the Treg phenotype in an inflammation-free background is critical to support the main conclusion of the study.</p><p>2. The authors are advised to reassess the experiments using tamoxifen-inducible Foxp3-CreERT2 as the intricacies of this system appear to have been overlooked. Tamoxifen treatment does not induce Foxp3-EGFP expression in these mice as Foxp3-EGFP is expressed irrespective of tamoxifen (doi: 10.1126/science.1191996). Tamoxifen treatment will induce Cre-mediated gene deletion in Foxp3 expressing cells, but the cells are already EGFP+. In order to observe these cells, the mice must be crossed with a Rosa26-driven, stop-floxed fluorescent reporter mouse (e.g., YFP, available at jax.org/strain/006148), which will have fluorescent reporter expression only in the cells with successful Cre activation. The bulk EGFP+ cells contain a mixture of 6PGD+/+ and 6PGD-/- Treg cells. Furthermore, Foxp3-CreERT2 is a notoriously inefficient system for successful Cre activation, with only 50% or less of Treg cells actually having Cre-mediated gene deletion following tamoxifen treatment in vivo. If there are constraints on completing the experiment with the reporter as recommended, the data in its current form may be omitted from the study.</p><p>3. In the Results section, the sentence &quot;As our preliminary studies showed that 6PGD but not G6PD blockade induces T cells activation (Figure 1—figure supplement 1 B-C). &quot; is truncated. The preliminary data shown in suppl. Figure 1B-C indicates that a 6PGD pharmacological inhibitor enhances IFN-γ production by in vitro activated CD4 T cells, not that it &quot;induces&quot; T cell activation: the text should be corrected accordingly. In supplemental figure 1, the effects of DHEA on cell viability are noticeable. Any activation defects on the cells are likely a secondary consequence. Is it possible to use a lower dose to avoid so much cell death? In Figure 1G, the sentence &quot;Lymphoproliferation was attributed to a higher number of CD4<sup>+</sup> and CD8<sup>+</sup> T cells in spleen/lymphoid organs should be corrected, since this figure shows frequencies and not counts. Further, Figure 1G only shows one plot, but it is from multiple organs according to the text. Are the other plots missing?</p><p>4. Regarding Treg frequency in Figure 2A, it is more informative to show the percentage of Foxp3+ in gated CD4 T cells, and also to show the gMFI of Foxp3 in gated Foxp3+ cells (it seems much lower in fl/fl mice; indeed this is confirmed by RT-PCR in Figure 2E). Is the difference between the two groups statistically significant? Statistics for frequencies and total numbers of Treg cells are missing. It is unclear why iTreg cells were used for figure 2C? A 50% reduction in Foxp3 gene expression, (Figure 2E), is substantial and seems incongruent with the claim of only a &quot;slight decrease&quot; in YFP MFI. Does direct Foxp3 staining and MFI quantification show the same result?</p><p>5. Figure 2—figure supplement 1D does not explain Treg plasticity since it refers to conventional effector T cell polarisation. The authors may consider removing this experiment from the manuscript. Figure 2—figure supplement 1 F-G-H presumably shows gated/sorted Foxp3+ cells: if this is the case, it needs to be clarified in the respective legend.</p><p>6. Figure 3B, and especially the meaning of the arrows, is unclear and may be omitted. Figure 3C shows substantial loss of Foxp3 gene expression with 6-AN treatment, but this does not appear to manifest in YFP expression as seen in Figure 3B. To check whether 6-AN affects iTreg polarization, the frequency of YFP+ cells and/or the gMFI of Foxp3-YFP should be assessed first in total CD4 T cells and not in gated YFP+ cells as apparently done here. In figure 3D-E, have YFP+ iTregs been sorted before assessing their suppressive function? In figure 3G, it is not clear what CONTROL means: is it the wild-type (not transgenic) mouse? The Treg gate looks very wide. Figure 3—figure supplement 1C is not mentioned in the text at the following point in the text: &quot;higher infiltration of T cells (both CD4<sup>+</sup> and CD8<sup>+</sup> cells)&quot;. Regarding Figure 3—figure supplement 1L-M, are these cells MDSCs or rather pro-inflammatory neutrophils? Some more profiling is needed to identify these cells as MDSCs.</p><p>7. Reiterating an earlier point, the analysis of Figure 4 should be performed in Treg cells isolated from an inflammation-free system.</p><p>8. Statistical analysis is to be provided for data in Figures 3 and 4C</p><p>9. As a more general point, it should be clarified that data (and supporting bibliography) refer not to conventional T cells polarising into T helper subsets but to Tregs becoming unstable and gaining T helper-like features, which is a defined process.</p><p>10. The precise mechanism through which 6PGD destabilizes Tregs may be epigenetic (as mentioned in the discussion) as also metabolic (for instance related to a higher glucose capture). See for instance the two recent papers 10.1038/s41586-021-03326-4 and 10.1038/s41586-020-03045-2. The discussion could be integrated with some more hypotheses and speculations on the underlying mechanisms.</p><p>11. The manuscript would benefit from careful editing since several statements are not adequately supported by the data or by the quoted references.</p><p><italic>Reviewer #1:</italic></p><p>The authors employ chemical inhibition as well as genetic approaches to block 6PGD activity and report striking phenotypes of loss of immune-suppression in mice carrying a Treg-specific deletion. These phenotypes, which are characterized in considerable detail support an important role for the enzyme in Treg activation and homeostasis. The study includes description of disease phenotypes and cellular properties, which is supported by transcriptional analysis and detailed metabolite analysis at the cellular level. Mechanistic insights underpinning these outcomes and the regulation of 6PGD in the Treg lineage, however, remain to be addressed.</p><p><italic>Reviewer #2:</italic></p><p>This paper demonstrate that 6PGD, a rate-limiting enzyme in oxidative pentose-phosphate pathway (PPP), modulates Treg metabolism and functions. Indeed, mice with a Treg-restricted 6PGD deficiency (either constitutive or inducible) spontaneously develop a multi-organ scurfy-like lethal disease, characterised by less suppressive and unstable Tregs, which also have a skewed metabolism toward glycolysis, Krebs cycle and non-oxidative PPP.</p><p>The main strengths of the manuscript are (I) the original identification of a role for PPP in immune regulation, (ii) the high quantity and quality of data, spanning through several mouse models and validated through several methodologies (flow cytometry, functional assays, RNASeq, biochemistry, metabolic tracing, etc).</p><p>The precise mechanism through which 6PGD destabilises Tregs has not been fully elucidated here, and it may be epigenetic (as mentioned in the discussion) as well as metabolic (for instance related to a higher glucose capture, see for instance the two recent papers 10.1038/s41586-021-03326-4 and 10.1038/s41586-020-03045-2): the discussion could be integrated with some more hypotheses and speculations on the underlying mechanisms. The manuscript would also benefit from a careful revision, since several statements are not sufficiently supported by the data or by the quoted references.</p><p><italic>Reviewer #3:</italic></p><p>Mice with Treg cell specific 6PGD deficiency develop a severe lymphoproliferative disease and succumb to early death, suggesting a loss of Treg cell immunosuppressive function. Treg cell frequency in these mice is apparently only slightly reduced and is mostly affected by a transcriptional reprogramming to resemble that of conventional T effector subsets. The core ideas of this manuscript have a lot of potential in the area of Treg immunometabolism, which currently lags behind conventional CD4 and CD8 literature.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><p>Thank you for submitting your article &quot;6-Phosphogluconate dehydrogenase (6PGD) a key checkpoint in reprogramming of Treg metabolism and function&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Apurva Sarin as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Satyajit Rath as the Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>The revised manuscript addresses most earlier comments. The following essential modifications are required in the description of the results to address issues remaining in the study.</p><p>1. The early onset of systemic inflammation in mice with an ablation of 6PGD may modulate the analysis of cell intrinsic 6PGD dependencies, a limitation not ruled out in the study. This may be indicated in the description of results linked to Figure 2—figure supplement 1 and Figure 4 (metabolic reprogramming).</p><p>2. As indicated in reference PMID: 2738173, the phenotypic analysis may not be sufficient to identify cells as MDSCs. Since this is a not a typical context of MDSC expansion, such as cancer, but of lung inflammation, neutrophils may have also been recruited.</p><p>3. In experiments utilizing in vitro generated (induced) Tregs (iTregs), this must be explicitly stated in the description of the experiment in the text and accompanying legends.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.67476.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1. Most experiments describing the Treg cell phenotype and function are in Foxp3Cre 6PGDfl/fl mice, which has significant systemic inflammation. This confounds Treg cell phenotypes that are presented (e.g., RNA-seq profile, in vitro suppression, ECAR, OCR, adoptive transfer). The Foxp3Cre 6PGDfl/fl system is appropriate for the in vivo profiling data of conventional CD4, CD8, and Treg cells, but not to conclude direct effects of 6PGD loss within Treg cells. The characterization of 6PGD deficient Treg cells should be undertaken in an inflammation-free system, using either mixed bone marrow chimera mice or an inducible-cre system (see the following comment). Alternatively, key analyses may be performed using Foxp3Cre/+ heterozygous females, only if they do not develop inflammation. Characterization of the Treg phenotype in an inflammation-free background is critical to support the main conclusion of the study.</p></disp-quote><p>Response to the comment consists of two parts: (1) we evaluated the key observations of Tregs in inflammation free condition. (2) The goal of current paper is reporting observed phenotype and function and we aim to address the mechanism of action in future studies.</p><p>The main goal of current manuscript is to demonstrate the key role of 6PGD (the key enzyme in oxidative PPP) in modulating Treg function. We understand that there are questions unanswered, notably the mechanism of action and possible effects of inflammatory condition on the observed phenotype. However, to fully answer these questions is beyond the current scope. We have highlighted “inflammatory condition” throughout the manuscript to keep in mind that targeting 6PGD in Tregs comes along with systemic inflammation.</p><p>Suffice to say, we have examined the key findings in inflammation free conditions:</p><p>– We have generated Tregs from wild type (WT) naïve CD4<sup>+</sup> T cells in the presence of 6PGD inhibitor (6-AN) and showed key findings as alteration of FoxP3/GATA3 expression, cytokine production shift and altered suppressive function (Figure 3A-E).</p><p>– We also showed comparable results in Tregs function (Figure 3H-O) using inducible FoxP3 mice (please see further details in response to comment 2) that provide inflammation free condition and the same inflammation baseline for both WT and 6PGD blocked Tregs.</p><p>– Furthermore, to evaluate metabolic shifts in Tregs in an inflammation free condition, we generated Tregs from naïve CD4<sup>+</sup> T cells within 4 days in vitro (therefore there was no inflammatory environment) and tracked Glc and Gln metabolism which showed a similar pattern of shift as Tregs isolated from 6PGD<sup>fl/fl</sup> FoxP3<sup>Cre</sup> mice (please see added Figure 4 supplementary figure 2 and Figure 4 supplementary figure 3).</p><p>It should be noted that it is highly unlikely to generate inflammation free condition by Chimeric models of 6PGD deletion as it would need several weeks to develop chimera, while even 3 weeks of 6PGD blockade induces massive inflammation that kill the mice after birth. This is the reason why we took the in vitro approach. However, per the reviewer’s suggestion, the inducible FoxP3 Cre (tamoxifen-inducible Foxp3-CreERT2) is useful as we examined (Please see response to Comment 2).</p><disp-quote content-type="editor-comment"><p>2. The authors are advised to reassess the experiments using tamoxifen-inducible Foxp3-CreERT2 as the intricacies of this system appear to have been overlooked. Tamoxifen treatment does not induce Foxp3-EGFP expression in these mice as Foxp3-EGFP is expressed irrespective of tamoxifen (doi: 10.1126/science.1191996). Tamoxifen treatment will induce Cre-mediated gene deletion in Foxp3 expressing cells, but the cells are already EGFP+. In order to observe these cells, the mice must be crossed with a Rosa26-driven, stop-floxed fluorescent reporter mouse (e.g., YFP, available at jax.org/strain/006148), which will have fluorescent reporter expression only in the cells with successful Cre activation. The bulk EGFP+ cells contain a mixture of 6PGD+/+ and 6PGD-/- Treg cells. Furthermore, Foxp3-CreERT2 is a notoriously inefficient system for successful Cre activation, with only 50% or less of Treg cells actually having Cre-mediated gene deletion following tamoxifen treatment in vivo. If there are constraints on completing the experiment with the reporter as recommended, the data in its current form may be omitted from the study.</p></disp-quote><p>We have adopted the tamoxifen-inducible Foxp3-CreERT2 model for the “proof of concept” study, especially as a model for an inflammation free condition. Although the tamoxifen induction does not induce deletion in 100% of Tregs (possibly 50% based on the mentioned reference), it was sufficient to reduce tumor growth (i.e. reduced Treg suppressive function in vivo) and suppressive capacity in suppression assay in vitro. This is important in the context of Comment 1 discussion. The mentioned reference has very nicely shown that gene deletion (50%) only happened upon Tamoxifen induction, supporting “target specificity” and “inflammation free condition at baseline”. Our data indicate that 6PGD did not need to be deleted in 100% of Tregs to show significant phenotype. So, while we have not done the suggested improved experiment, the current data support our goal of defining 6PGD’s role in modulating Tregs function. We have added a statement in the result section to reflect the incomplete induction of FOXP3 deletion in the model used.</p><disp-quote content-type="editor-comment"><p>3. In the Results section, the sentence &quot;As our preliminary studies showed that 6PGD but not G6PD blockade induces T cells activation (Figure 1—figure supplement 1 B-C). &quot; is truncated. The preliminary data shown in suppl. Figure 1B-C indicates that a 6PGD pharmacological inhibitor enhances IFN-γ production by in vitro activated CD4 T cells, not that it &quot;induces&quot; T cell activation: the text should be corrected accordingly. In supplemental figure 1, the effects of DHEA on cell viability are noticeable. Any activation defects on the cells are likely a secondary consequence. Is it possible to use a lower dose to avoid so much cell death? In Figure 1G, the sentence &quot;Lymphoproliferation was attributed to a higher number of CD4<sup>+</sup> and CD8<sup>+</sup> T cells in spleen/lymphoid organs should be corrected, since this figure shows frequencies and not counts. Further, Figure 1G only shows one plot, but it is from multiple organs according to the text. Are the other plots missing?</p></disp-quote><p>The sentence was corrected based on the comment to show enhanced IFN-γ production and not “induction of activation” in T cells.</p><p>The main point of supplemental figure 1B-C was to show noticeable effect of DHEA on activated T cells viability. While the same concentration of 6-AN and DHEA inhibitors (10 µM) were used, DHEA instigated poor T cells viability but not 6-AN. This shows the critical role of G6PD in cells viability and therefore its targeting is not tolerable by T cells. Meanwhile, blocking 6PGD was tolerable by the activated T cells and resulted in higher IFN-g production presumably by the induced metabolic shifts. This preliminary experiment provided the reason why we investigated 6PGD’s role in T cell activation. Text on page 4 was revised to substantiate this point.</p><p>For Figure 1G, the word “Count” was corrected for “Frequency”. (Count per organ is presented in Figure 1E). We have evaluated both lymph nodes and spleens for markers mentioned in Figure 1G-K. As both spleen and lymphnodes show similar pattern or responses, we presented splenocytes data as an example. We have revised the relevant Results text on page 5 accordingly. Moreover, the enlarged spleen and lymph node size shown in Figure 1D suggests lymphoproliferation in both spleen and lymph nodes.</p><disp-quote content-type="editor-comment"><p>4. Regarding Treg frequency in Figure 2A, it is more informative to show the percentage of Foxp3+ in gated CD4 T cells, and also to show the gMFI of Foxp3 in gated Foxp3+ cells (it seems much lower in fl/fl mice; indeed this is confirmed by RT-PCR in Figure 2E). Is the difference between the two groups statistically significant? Statistics for frequencies and total numbers of Treg cells are missing. It is unclear why iTreg cells were used for figure 2C? A 50% reduction in Foxp3 gene expression, (Figure 2E), is substantial and seems incongruent with the claim of only a &quot;slight decrease&quot; in YFP MFI. Does direct Foxp3 staining and MFI quantification show the same result?</p></disp-quote><p>We added the percentage of Foxp3+ in gated CD4 T cells in Figure 2A. We also added Figure 2B to show gMFI of Foxp3 in gated Foxp3+ cells. Statistical analysis for the two panels are provided to show significantly lower frequency of FoxP3+ T cells in 6PGD<sup>fl/fl</sup> FoxP3<sup>Cre</sup> group. Figure 2C (original) was eliminated to prevent confusion.</p><p>Decreased FoxP3 expression (Figure 2E) is consistent with lower levels of Foxp3 staining in CD4<sup>+</sup> cells and gMFI quantifications (Figure 2A-B) in 6PGD blocked Tregs. This result was also reproduced when Tregs were generated with 6PGD inhibitor 6-AN, in vitro (Figure 3C). About 50% decrease in YFP+ cells is also evident in 6PGDfl/fl FoxP3Cre mice (Data not shown in paper; Please see <xref ref-type="fig" rid="sa2fig1">Author response image 1</xref>) Please note that Figure 2D is representative of “Sorted YFP+ cells” that have been used in all YFP+ sorted experiment (e.g. Figure 2E-G and Figure 2—figure supplement 1 and Figure 4 and supplements). We revised the manuscript text on page 6 to clarify this.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><caption><title>YFP expression in CD4<sup>+</sup> gated cells from mice spleen.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67476-sa2-fig1-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>5. Figure 2—figure supplement 1D does not explain Treg plasticity since it refers to conventional effector T cell polarisation. The authors may consider removing this experiment from the manuscript. Figure 2—figure supplement 1 F-G-H presumably shows gated/sorted Foxp3+ cells: if this is the case, it needs to be clarified in the respective legend.</p></disp-quote><p>We removed the Figure 2—figure supplement 1D. In case of Figure 2—figure supplement 1 F-G-H (original and E-F-G of revised figure) graphs show “Splenic CD4<sup>+</sup> T cells” as mentioned in the figure legends. While 6PGD blocked Tregs show altered markers of CD4<sup>+</sup> T subsets (revised Figure 2—figure supplement 1A-C and also Figure 2G and Figure 3C), E-G of revised figure 2—figure supplement 1 provide additional information regarding CD4<sup>+</sup> T subsets and indicate general shift of CD4<sup>+</sup> T cells toward Th1, Th2 and Th17 cells subsets in 6PGD<sup>fl/fl</sup> FoxP3<sup>Cre</sup> mice. Text was clarified in page 7.</p><disp-quote content-type="editor-comment"><p>6. Figure 3B, and especially the meaning of the arrows, is unclear and may be omitted. Figure 3C shows substantial loss of Foxp3 gene expression with 6-AN treatment, but this does not appear to manifest in YFP expression as seen in Figure 3B. To check whether 6-AN affects iTreg polarization, the frequency of YFP+ cells and/or the gMFI of Foxp3-YFP should be assessed first in total CD4 T cells and not in gated YFP+ cells as apparently done here. In figure 3D-E, have YFP+ iTregs been sorted before assessing their suppressive function? In figure 3G, it is not clear what CONTROL means: is it the wild-type (not transgenic) mouse? The Treg gate looks very wide. Figure 3—figure supplement 1C is not mentioned in the text at the following point in the text: &quot;higher infiltration of T cells (both CD4<sup>+</sup> and CD8<sup>+</sup> cells)&quot;. Regarding Figure 3—figure supplement 1L-M, are these cells MDSCs or rather pro-inflammatory neutrophils? Some more profiling is needed to identify these cells as MDSCs.</p></disp-quote><p>We believe that the reviewer meant arrows in the schemes of Figure 3A (original) being unclear (as the Figure 3B was a flowcytometry graph). We have removed the figure 3A panel.</p><p>The original Figure 3B (now Figure 3A) shows the percentage of YFP+ cells. The YFP gMFI (gated on CD4<sup>+</sup> cells) for respective treatments was determined and presented in bar graph as new Figure 3B. Lower YFP gMFI in 6-AN treated cells is akin to lower FoxP3 mRNA levels detected by Real-time PCR (Figure 3C).</p><p>In figure 3D-E, YFP+ iTregs have been sorted before assessing their suppressive function. We clarified this in the figure legend.</p><p>In figure 3G, “Control” is the wild type mice. These cells are used to determine autofluorescence baseline for eGFP expression. Graph label was changed from “Control (EGFP-)” to “WT (EGFP-)”. Gating was done based on the WT baseline.</p><p>Text was corrected on page 9 to cite Figure 3—figure supplement 1C after reporting &quot;higher infiltration of T cells (both CD4<sup>+</sup> and CD8<sup>+</sup> cells) in the lung.</p><p>Figure 3—figure supplement 1L-M illustrated MDSCs accumulation in inflamed lungs, which is an additional marker along with other results to show uncontrolled allergic responses in lung of mice with 6PGD deletion in their Tregs. We used CD11b+Ly6G+ cells as marker of PMN MDSCs (ref to: PMID: 27381735 and PMID: 32549755). To investigate details of MDSCs properties upon 6PGD blockade is beyond the scope of this study.</p><disp-quote content-type="editor-comment"><p>7. Reiterating an earlier point, the analysis of Figure 4 should be performed in Treg cells isolated from an inflammation-free system.</p></disp-quote><p>To analyze Tergs metabolism in an inflammation-free system, we generated Tregs in vitro for the tracing study. Results are presented in Figure 4—figure supplement 2 and Figure 4—figure supplement 3. These results indicate a similar trend of metabolic shifts in 6PGD deficient Tregs isolated form 6PGD<sup>fl/fl</sup> FoxP3<sup>Cre</sup> mice and 6PGD deleted Tregs generated in vitro in the inflammation free environment.</p><disp-quote content-type="editor-comment"><p>8. Statistical analysis is to be provided for data in Figures 3 and 4C</p></disp-quote><p>Statistical analysis was done for the mentioned figures and bar graphs provided.</p><disp-quote content-type="editor-comment"><p>9. As a more general point, it should be clarified that data (and supporting bibliography) refer not to conventional T cells polarising into T helper subsets but to Tregs becoming unstable and gaining T helper-like features, which is a defined process.</p></disp-quote><p>Text was corrected on page 26 for the mentioned point.</p><disp-quote content-type="editor-comment"><p>10. The precise mechanism through which 6PGD destabilizes Tregs may be epigenetic (as mentioned in the discussion) as also metabolic (for instance related to a higher glucose capture). See for instance the two recent papers 10.1038/s41586-021-03326-4 and 10.1038/s41586-020-03045-2. The discussion could be integrated with some more hypotheses and speculations on the underlying mechanisms.</p></disp-quote><p>Discussion on page 14 was revised to discuss more potential mechanisms also referring the above references.</p><disp-quote content-type="editor-comment"><p>11. The manuscript would benefit from careful editing since several statements are not adequately supported by the data or by the quoted references.</p></disp-quote><p>We revised the text carefully to be sure that is representative of our results or the literature.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>The revised manuscript addresses most earlier comments. The following essential modifications are required in the description of the results to address issues remaining in the study.</p><p>1. The early onset of systemic inflammation in mice with an ablation of 6PGD may modulate the analysis of cell intrinsic 6PGD dependencies, a limitation not ruled out in the study. This may be indicated in the description of results linked to Figure 2—figure supplement 1 and Figure 4 (metabolic reprogramming).</p></disp-quote><p>Text was modified to point out the limitation for the findings on Tregs isolated from pro-inflammatory mice. This include page 6 and 7 for Figure 2—figure supplement 1 and page 10 for Figure 4 (marked by track change).</p><disp-quote content-type="editor-comment"><p>2. As indicated in reference PMID: 2738173, the phenotypic analysis may not be sufficient to identify cells as MDSCs. Since this is a not a typical context of MDSC expansion, such as cancer, but of lung inflammation, neutrophils may have also been recruited.</p></disp-quote><p>We removed the “MDSC” from the text and figure legend and indicated only CD11b+ Ly6G+ cells along with the mentioned reference (page 10 and Figure 3—figure supplement 1 legends). These text changes were made as we did not delineate CD11b+ Ly6G+ cells to be MDSC or neutrophils, which is beyond the scope of current study.</p><disp-quote content-type="editor-comment"><p>3. In experiments utilizing in vitro generated (induced) Tregs (iTregs), this must be explicitly stated in the description of the experiment in the text and accompanying legends.</p></disp-quote><p>We clarified the text and figure legends for the Tregs generation in vitro, anywhere describing these cells. This includes, figure 3, Figure 4—figure supplement 2 and Figure 4—figure supplement 3 (text and figure legends).</p></body></sub-article></article>